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’ INTRODUCTION
According to the WHO,1 1.7 million people died from
tuberculosis (TB) in 2009 and more than 2 billion people
(constituting one-third of the world’s population) are infected
with TB. Among the 9.4 million new TB cases reported in 2009,
an estimated 1.11.2 million (1113%) suffer from HIV coin-
fection. Hence, TB, a contagious infectious disease, is regarded as
the leading cause of death due to an infectious agent among
adults worldwide and a major threat to global health.2 The
disease establishes mainly in the pulmonary system and is caused
by somemycobacteria of theMycobacterium tuberculosis complex,
predominantly Mycobacterium tuberculosis.3
Active TB is treated by chemotherapy with so-called first-line
drugs.46 From the many trials conducted in the past 50
60 years, two standard regimens emerged which are recommended
by theWHO and consist of a two-month daily treatment of either
isoniazid, rifampin, pyrazinamide, and streptomycin or isoniazid,
rifampin, pyrazinamide, and ethambutol, followed by further four
months daily or intermittent doses of isoniazid and rifampin.
Unfortunately, the long treatment times and the side effects7 of
the drugs (especially hepatotoxicity) lead to a high proportion of
noncompliance patients. This and the rise of the HIV pandemic8
in the early 1980s led to the emergence of multidrug resistant9
(MDR) and, more recently, even extensively drug resistant10
(XDR) strains. MDR-TB is defined as resistance to the action of
at least isoniazid and rifampin, and its treatment requires the
inclusion of so-called second-line drugs such as aminoglycosides,
fluoroquinolones, and second-line bacteriostatics. XDR bacteria
are MDR and also resistant to fluoroquinolones and at least one
injectable antibiotic. The XDR-tuberculosis is virtually untrea-
table. The increasing incidences of MDR- and XDR-tuberculosis
urgently demand novel drugs for therapy of tuberculosis. The
side-effects of current drugs, the high costs of second-line drugs,
and the lack of well-established guidelines for the treatment of
MDR-TB and XDR-TB require alternative approaches to target
tuberculosis.11,12
Traditionally, the only known pathway for de novo synthesis
of thymidylate which is essential for most eubacteria, plants, and
eukaryotic cells was by thymidylate synthase (TS or ThyA).13
This enzyme catalyzes the reductive methylation of 20-deoxy-
uridine-50-monophosphate (dUMP) to 20-deoxythymidine-50-
monophosphate using R-N5-N10-methylene-5,6,7,8-tetrahydro-
folate (CH2THF) as a methylene and hydride donor, resulting in
the formation of 7,8-dihydrofolate (DHF). In the classical ThyA
cycle, formation of thymidylate must be coupled with reduction
of DHF to THF catalyzed by dihydrofolate reductase (DHFR) and
remethylenation by serinehydroxymethyl transferase (SHMT).
However, it has been shown that several microorganisms lack
the genes encoding for ThyA and DHFR but are still fully viable
in thymidine-deficientmedia. This led to the discovery of the ThyX
gene, which encodes for the ThyX protein, a flavin-dependent
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ABSTRACT: A series of 5-substituted 20-deoxyuridine mono-
phosphate analogues has been synthesized and evaluated as
potential inhibitors of mycobacterial ThyX, a novel flavin-
dependent thymidylate synthase in Mycobacterium tuberculosis.
A systematic SAR study led to the identification of compound
5a, displaying an IC50 value against mycobacterial ThyX of
0.91 μM. This derivative lacks activity against the classical myco-
bacterial thymidylate synthase ThyA (IC50 > 50 μM) and
represents the first example of a selective mycobacterial FDTS
inhibitor.
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thymidylate synthase (FDTS) which is rare in eukaryotes and
absent in humans.14 ThyX uses CH2THF only as one-carbon
donor, whereas reduced flavin adenine dinucleotide (FADH2)
serves as a hydride donor. Members of the ThyX family are
NAD(P)H-oxidases because catalysis requires the presence of
NAD(P)H to furnish sufficient amounts of FADH2 via reduction
of FAD. Furthermore, ThyX shows no structural similarity with
ThyA15 and there is no sequence similarity between ThyA and
ThyX proteins, allowing the design of selective ThyX-inhibitors
as a novel approach to target tuberculosis. While some pathogens
solely rely on ThyX, genetic analysis revealed thatM. tuberculosis
carries genes encoding for ThyA, ThyX, and DHFR.14 Transpo-
son site hybridization studies have shown that the ThyX gene
is required for mycobacterial growth and survival within
macrophages.16,17 Nonetheless, it remains unclear under which
conditions either gene is activated. Steady-state kinetic analyses
of M. tuberculosis revealed that dTMP-synthesis proceeds with
very low catalytic rates in both enzymes, thereby suggesting that
the true biological substrates still remain to be found.18 These
findings may be in accordance with the extremely low growth
rates of M. tuberculosis and could be an indicator for down-
regulation of dTMP-production.
In the past few years, several studies to reveal the biochemical
reaction mechanism were documented in literature.19,20 Initially,
an active site catalytic serine was assumed to nucleophilically
attack C-6 of dUMP in a Michael-type reaction to give rise to an
enolate at C-4 and C-5, which in turn attacks the iminium ion of
CH2THF to form the new CC bond in dTMP. This
dUMPCH2THF adduct subsequently undergoes β-elimina-
tion to install an exo-methylene bond between C-5 and C-7,
which is reduced by FADH2 in the final step to yield dTMP.
However, the following facts led to the supersession of this
mechanism: (i) The active site serine is too far away from the C-6
of dUMP, as shown by Sampathkumar et al., who provided a
crystal structure21 of Mtb-ThyX in complex with the substrate
analogue 5-Br dUMP and FAD, and only conformational
changes in the enzyme would be able to lead to nucleophilic
catalysis. (ii) No general base is located near this putative serine
which would be required to enhance its otherwise too weak
nucleophilicity. (iii) Point mutation studies in Thermotoga
maritima have shown that the enzyme was still active after
mutation of this serine to either an alanine or cysteine. Recently,
Koehn et al. performed the reaction in 99% D2O which resulted
in incorporation of deuterium in the 6-position. These new
intriguing findings led to the suggestion of an alternative reaction
mechanism22 (Scheme 1) which contains the following two
distinctive key steps: (i) a hydride equivalent is transferred
directly from FADH2 to the C-6 of dUMP (part 2, step 2) and
(ii) an unusual 1,3-hydride shift from C-6 to the exo-methylene
C-7 in the last step furnishes dTMP (part 3, step 5). Steps 3 and 4
correspond to the previously proposed mechanism and are
considered as logical on the mechanistic pathway toward dTMP.
An alternative additionelimination mechanism involved in the
last step could be ruled out when the reaction was performed
using 6D-dUMP in H2O because the formation of nondeuter-
ated dTMP could not be observed.
Although ThyX is an attractive target for antimycobacterial
drug design, the only known inhibitors are 5-F and 5-BrdUMP.23
However, both are known to act as human ThyA inhibitors
and are therefore of no interest for antibacterial therapy.2428
Up to now, no selective inhibitors of mycobacterial FDTS
are known in literature. In this paper, we describe the synthesis
Scheme 1. Current Biochemical Reaction Mechanism Involving Direct Hydride Transfer and 1,3-Hydride Shift
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of a novel series of C-5 substituted 20-dUMP analogues and
their evaluation as inhibitors of mycobacterial ThyX and ThyA
(Scheme 2).
’RESULTS AND DISCUSSION
Chemistry. To have easy access to C-5 variation of the dUMP
scaffold, 5-iodo-20-deoxyuridine 7a was considered as ideal
starting material. It is commercially available or, alternatively, it
can be prepared from 20-deoxyuridine according to a protocol
described in literature.29
5-(2-cyanovinyl)-deoxyuridine 8 was synthesized via a Heck
reaction of 7a with acrylonitrile in the presence of a Pd(0) cata-
lyst and a tertiary amine in DMF at elevated temperature.3032
Phosphorylation of the primary hydroxyl group of compound 8
according to the procedure by Sowa and Ouchi33 yielded the
desired monophosphate derivative 1 (Scheme 3).
To introduce a phenyl group at position 5 of the uracil moiety,
Pd-catalyzed Suzuki cross-coupling reaction34 of 7a has been
performed with suitable boronic acids. Attempts using various
bases (K2CO3, Na2CO3, NaOH, KF) in an organic solvent/H2O
mixture predominantly led to dehalogenation. After carefully
Scheme 2. Structures of Synthesized ThyX-Inhibitors
Scheme 3a
aReagents and conditions: (a) CH2CHCN, Pd(PPh3)4, (n-Bu)3N, DMF, 80 C; (b) boronic acid, Pd(PPh3)4, CsF, DMF/H2O, 60 C; (c) POCl3, pyr,
H2O, CH3CN/PO(OMe)3, 0 C.
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tuning reaction conditions, it was found that successful cross
coupling could be achieved with CsF as base in a mixture of DMF
and water as solvent (Scheme 3). Under these reaction circum-
stances, only small amounts of 20-deoxyuridine were detected.
Phosphorylation of compounds 9ab afforded the 5-aryl-20-
dUMP analogues 2ab.
Long-chain acetylenic compounds 3ab have been synthe-
sized via palladium-catalyzed Sonogashira cross-coupling of
suitable acetylenes with unprotected 5-iodo nucleosides as the
key step (Scheme 4).35,36 Compounds 10a and 10b were
accessible from unprotected 5-iodo-20-deoxyuridine 7a and
1-(β-D-arabinofuranosyl)-5-iodoracil 7b, respectively, by Sono-
gashira cross-coupling with 1-dodecyne with a slightly modified
workup than the one described in the literature. Yoshikawa
phosphorylation37,38 (POCl3/proton sponge/trimethyl phos-
phate) finally furnished compounds 3a and 3b (Scheme 4).
The arabino-based compounds were synthesized from 1-(β-D-
arabinofuranosyl)-5-iodoracil,39 7b, which was prepared by
reaction of 1-(β-D-arabinofuranosyl)uracil39,40 with I2 in
HNO3/CHCl3.
For the introduction of an amide functionality into this long
chain, acetylated 5-iodo nucleosides 11a29 and 11b41,42 were
used as starting material (Scheme 5). For the synthesis of
derivatives 4a and 4b, bearing an N-butyl-6-heptynamide chain,
compounds 11a and 11b were subjected to Pd-catalyzed cross-
coupling with 6-heptynoic acid,43 followed by DIC/HOBt
mediated coupling with n-butylamine.44 Deprotection of the
acetyl groups under alkaline conditions,29 followed by phosphor-
ylation, yielded the desired final compounds 4a and 4b. On the
other hand, the synthesis of 5-propargylamide derivatives 5ad
and 6ab was performed in a divergent manner. The acetylene
moieties were synthesized through condensation reaction of
propargylamine with suitable acyl chlorides, yielding 15ad as
shown in Scheme 6.45
The introduction of the amide-containing terminal acetylenes
15ad at position 5 of the uracil ring was achieved via a
Sonogashira cross-coupling, followed by deacetylation affording
nucleoside analogues 18ad (Scheme 7).
Phosphorylation of derivative 18a was problematic. The
standard method previously used (POCl3/proton sponge/tri-
methyl phosphate) only gave unsatisfactory results with low
yields and difficult purification due to the presence of side
products. However, repeated purification (flash chromatogra-
phy and HPLC) led to the isolation of the pure nucleoside
Scheme 4a
aReagents and conditions: (a) 1-dodecyne, Pd(PPh3)4, CuI, NEt3, DMF, rt; (b) POCl3, proton sponge, PO(OMe)3, 0 C.
Scheme 5a
aReagents and conditions: (a) Ac2O, DMAP, NEt3, CH3CN, rt; (b) 6-heptynoic acid, Pd(PPh3)4, CuI, DIPEA, DMF, rt; (c) n-butylamine, DIC, HOBt,
DCM, 0 C to rt; (d) NaOMe, MeOH, rt; (e) POCl3, proton sponge, PO(OMe)3, 0 C.
4851 dx.doi.org/10.1021/jm2004688 |J. Med. Chem. 2011, 54, 4847–4862
Journal of Medicinal Chemistry ARTICLE
monophosphate derivative 5a. For the phosphorylation of deri-
vatives 18bd, the protocol employed by Sowa and Ouchi33,46
was evaluated in which the addition of H2O to the reaction
mixture was reported to enhance the reaction rate. Because of the
poor solubility of derivatives 18bd in CH3CN, a mixture of
acetonitrile and trimethyl phosphate was used as solvent. Un-
fortunately, these reaction conditions (POCl3, pyridine, H2O in
CH3CN/PO(OMe)3) were not compatible with the acetylenic
group. However, the desired analogues 5b and 5c could be
obtained in 96% and 92% purity, respectively, albeit only after a
second HPLC purification step. In the case of the desired
phenacylamide 5d, considerable amounts of the corresponding
keto compound 19, due to hydration of the triple bond, were
identified by NMR spectroscopy (Scheme 7). The 1H NMR
spectrum shows two distinct singlets at δ = 7.98 and 8.36 ppm,
which were assigned to H-6 in derivatives 5d and 19 in a ratio of
3.26:1, respectively. Furthermore, as expected, the 13C NMR
spectrum shows a clear peak at δ = 199.2 ppm for the keto-
carbonyl group, whereas both amide carbonyl peaks of 5d and 19
overlap at δ = 174.2. These findings were confirmed by mass
Scheme 6a
aReagents and conditions: (a) acyl chloride, DIPEA, DCM, 0 C to rt; (b) hexyl isocyanate, DCM, 0 C to rt; (c) thionyl chloride, reflux;
(d) propargylamine, NEt3, DCM, 0 C to rt.
Scheme 7a
aReagents and conditions: (a) acetylene 15ad, Pd(PPh3)4, CuI, DIPEA, DMF, rt; (b) NaOMe, MeOH, rt; (c) POCl3, proton sponge, PO(OMe)3,
0 C; (d) POCl3, H2O, pyr, CH3CN/PO(OMe)3, 0 C; (e) dibenzyl phosphate, PPh3, DIAD, THF, rt; (f) TMSI, CH3CN, 10 C.
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spectrometry. The ()-ESI mass spectrum of this mixture shows
two peaks atm/z = 478 and 496, corresponding to the [MHþ]
peak of 5d and 19, respectively.
Attempts to separate the desired acetylenic compound from its
hydrated form by RP-HPLC were unsuccessful, and therefore
alternatives were sought. Compound 18d was coupled with
dibenzyl phosphate under Mitsunobu conditions47 (PPh3,
DIAD, THF), furnishing the corresponding nucleoside dibenzyl
phosphate triester 20. To our disappointment, TMSI-mediated
debenzylation48 equally resulted in an inseparable mixture of 5d
and 19 in a ratio of 2.14:1 according to 1H NMR spectroscopy.
Finally the problem has been solved by using the method of
Tener.49 Thus, 5-iodo-30-O-acetyl-20-deoxyuridine 22,5052 pre-
pared in three steps from 5-iodo-20-deoxyuridine 7a (tritylation,
acetylation, and detritylation), was coupled with acetylene 15d,
yielding 30-O-acetylated derivative 23. DCC-coupling of 23 with
2-cyanoethyl phosphate (pyridinium salt) in anhydrous pyridine,
followed by deprotection with 1 M NaOH at 100 C for a few
minutes, finally gave pure 5d after purification, however in only
16% yield (Scheme 8). The same strategy was used for the
synthesis of dUMP derivatives with sulfonamide and urea-
containing acetylene moieties. Reaction of sodium 1-heptane-
sulfonate in neat thionyl chloride,53 followed by condensation of
the resulting sulfonyl chloride with propargylamine,54 furnished
acetylene 16 (Scheme 6). Similarly, condensation of propargy-
lamine with hexyl isocyanate yielded acetylenic urea 17.55 Cross-
coupling reaction of 22 with 16 proceeded smoothly, affording
compound 24, whereas the corresponding urea derivative 25
could not be obtained in pure form but was used in the
subsequent phosphorylation step without any further attempt
of purification. Addition of HOBt (1 equiv) did not lead to any
significant improvement; sulfonamide monophosphate 6a was
obtained in 11% yield. For the synthesis of urea monophosphate
6b, the reaction was carried out at 40 C together with the
addition of HOBt (1 equiv). Again, no substantial increase in
yield of the desired product (9%) could be achieved (Scheme 8).
Biological Evaluation and StructureActivity Relation-
ship Study. Compounds were evaluated for their inhibitory
activity against mycobacterial ThyX and ThyA. Cloning of the
ThyX gene, protein expression, and purification was done as
published previously.21 The inhibition of ThyX-catalyzed dTMP
synthesis was measured in a standard radioactive assay56,57 using
purified ThyX-protein and [5-3H]-dUMP as a radiolabeled
substrate. The amount of tritiated water released during the
reaction was measured by liquid scintillation counting. The thyA
gene was expressed in E. coli and the expressed His(6)-tagged
enzymes were purified by nickel-chelate chromatography. The
inhibition of dTMP-synthesis by ThyA was measured in a
standard photometric assay58 on a purified ThyA-protein. The
extent of inhibition found is based on a decrease of absorption of
DHF (which is formed during the biochemical transformation)
at 340 nm in the presence of an inhibitor (see Experimental
Section).
The crystal structure21 of the ThyX-FAD-5-BrdUMP complex
shows that the substrate analogue is buried completely in a deep
pocket. The oxygen atoms of the phosphate moiety as well as the
nitrogen and oxygen atoms of the pyrimidine ring have crucial
interactions with numerous highly conserved active site residues,
Scheme 8a
aReagents and conditions: (a) DMTrCl, DMAP, NEt3, pyr, rt; (b) Ac2O, DMAP, NEt3, CH3CN, rt; (c) TCA, DCM, rt; (d) acetylene 15d, 16, or 17,
Pd(PPh3)4, CuI, DIPEA, DMF, rt; (e) 2-cyanoethyl phosphate, DCC, pyr, rt; (f) 1MNaOH, 100 C; (g) 2-cyanoethyl phosphate, DCC, HOBt, pyr, rt;
(h) 2-cyanoethyl phosphate, DCC, HOBt, pyr, 40 C.
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Table 1. Inhibition of Mtb-ThyX and Mtb-ThyA by Compounds 17
aValues are means of three independent experiments. b 5-F dUMP used as positive control. c 93% purity. d 92% purity.
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notably arginine, glutamic acid, and aspartic acid. As this 50-O-
monophosphate group is critical for binding of 5-Br-dUMP, all
synthesized nucleosides within this study have been phosphory-
lated, affording the corresponding nucleotides that have been
evaluated as potential mycobacterial ThyX and ThyA inhibitors.
Furthermore, the pyrimidine ring of 5-BrdUMP and the iso-
alloxazine ring of FAD are close enough to interact via hydrogen
bonds and π-stacking. Therefore, the pyrimide ring system of
dUMP has been kept intact in the search for novel mycobacterial
ThyX inhibitors. The C-5 position of dUMP has been subjected
to extensive structural modifications using human ThyA as drug
target. In this paper, a similar strategy was followed in order to
discover novel mycobacterial ThyX inhibitors based on a dUMP
scaffold. Compounds were initially evaluated at a concentration
of 50 μM in the ThyX as well as in the ThyA assay. Compounds
displaying more than 50% inhibition were subjected to do-
seresponse curves in order to determine IC50 values. In both
assays, 5-F dUMP was included as reference compound and
positive control.
The SAR study started with the exploration of relatively small
modifications at the C-5-position of the uracil base. Introduction
of a cyanovinyl moiety in compound 1 confers good inhibitory
activity of mycobacterial ThyX (Table 1, IC50 = 7.4 μM),
although no inhibitory effect on mycobacterial ThyA could be
observed.
To probe if ThyX can accommodate sterically more demand-
ing substituents at position 5, aryl groups were introduced via
Suzuki cross-coupling reactions. The 5-(4-fluorophenyl) analo-
gue 2a exhibits good activity against ThyX (IC50 = 10 μM),
whereas no activity could be determined against ThyA. On the
other hand, the 5-(3-methoxyphenyl) analogue 2b shows no
activity against both enzymes. It indicates that the nature of the
substitution pattern on the phenyl ring has a large influence on
the biological activity.
Recently, Johar et al. disclosed arabinonucleoside analogues
with a long alkynyl side chain at the 5-position of the uracil
moiety that exhibited high levels of antimycobacterial activity in
vitro (MIC90 = 15 μg/mL).59 This observation prompted us to
study the effect of a long-chain alkynyl group at C-5 of uridylate
on mycobacterial ThyX and ThyA activity. Indeed, 5-dodecynyl-
dUMP 3a exhibits moderate ThyX inhibition (IC50 = 28 μM)
but has no effect on ThyA. The corresponding arabino analogue
3b completely lacks activity against both enzymes.
To further explore the SAR, functional groups were intro-
duced into the alkyl chain of derivatives 3a and 3b. The insertion
of an amide group in the center of the long alkyl chain afforded
compound 4a, which was 3-fold more potent in the ThyX assay
when compared with its long-chain analogue 3a. To our dis-
appointment, again, the corresponding arabino congener 4b was
completely devoid of thymidylate synthase inhibitory activity
(IC50 > 50 μM). Consequently, any further effort on the
synthesis of corresponding arabino derivatives was discontinued
and, in subsequent studies, we solely focused on the design and
synthesis of dUMP analogues. Shifting the amide functional
group closer toward the nucleobase furnished propargylamide
derivative 5a, which is 1 order of magnitude more potent (IC50 =
0.9 μM) than its congener 4a.
To probe the influence of the arm length, the total number of
carbon atoms of the alkynyl chain of 5a (12 carbon atom) was
decreased to a total number of 10 (compound 5b) and 8 atoms
(compound 5c), resulting in a 10- to 30-fold decrease of ThyX
inhibition, respectively. Similarly, the presence of a phenyl ring in
N-propargyl phenacylamide derivative 5d led to a decreased
ThyX inhibitory activity, displaying IC50 values of 7.3 μM. None
of these derivatives shows any appreciable ThyA inhibition.
A long chain consisting of 12 carbon atoms turned out to be
optimal for ThyX inhibition. Therefore, the total lengths of 12
atoms, as well as the propargylamine moiety, were preserved and
the functional group was modified in a further round of optimi-
zation. The amide group of compound 5a was replaced by a
sulfonamide moiety and a urea functionality, affording com-
pounds 6a and 6b, respectively. Both analogues show a 5-fold
drop in ThyX inhibition when compared to the amide congener
5a and completely lack activity against ThyA.
’CONCLUSION
The increasing incidences of resistant M. tuberculosis bacteria
urgently demand novel drugs for therapy of tuberculosis. How-
ever, no new anti-TBC drugs have been brought to the market in
the last 30 years. The last drug with a new mechanism of action
approved for TB was rifampicin (which was already discovered in
1963). Therefore, there is an urgent need for new antimycobac-
terial drugs with new modes of action to potentially avoid cross-
resistance. In this paper, mycobacterial ThyX has been selected as
a promising target for the development of novel antibacterial
drugs. Starting from the natural substrate, dUMP, a SAR study
was carried out in which structural variation at C-5 of the uracil
moiety was introduced. This work led to the discovery of a novel
series of 5-alkynyl dUMP analogues from which the most potent
congener (compound 5a) displays an IC50 value of 0.91 μM
against ThyX. The high polarity of this compound makes it very
unlikely that it will be able to cross the cell membrane of
M. tuberculosis and therefore it has not been tested for its anti-
microbial activity. Compound 5a completely lacks activity against
mycobacterial ThyA. To our knowledge, this is the first time a
selective mycobacterial FDTS inhibitor is reported. Up to now,
we have no rationale to explain the observed selectivity. Co-
crystallization of compound 5a with the mycobacterial ThyX
enzyme should reveal the binding mode of compound 5a and
might explain the selective mycobacterial ThyX inhibition.
Although compound 5a shows promising activity against the
ThyX enzyme, the presence of the phosphate moiety hampers its
further development. Further medicinal chemistry efforts will
be necessary to improve its drug-like characteristics in order to
have access to compounds which are useful for testing in a
bacterial assay.
’EXPERIMENTAL SECTION
Chemistry. For all reactions, analytical grade solvents were used.
Dry acetonitrile, pyridine, and MeOH were obtained by distillation over
CaH2. Dry DCM, DMF, and THF were purchased from commercial
suppliers. All moisture-sensitive reactions were carried out in oven-dried
glassware (120 C). 1H and 13C NMR spectra were recorded with a
Bruker Advance 300 (1H NMR, 300 MHz; 13C NMR, 75 MHz; 31P
NMR, 121 MHz) or 500 MHz (1H NMR, 500 MHz; 13C NMR,
125 MHz) spectrometer using tetramethylsilane as internal standard for
1H NMR spectra and DMSO-d6 (39.52 ppm) or CDCl3 (77.16 ppm) for
13C NMR spectra. Abbreviations used are: s = singlet, d = doublet, t =
triplet, q = quartet, m =multiplet, br s = broad signal. Chemical shifts are
expressed in parts per million (ppm). Coupling constants are expressed
in hertz (Hz). Mass spectra are obtained with a Finnigan LCQ advan-
tage Max (ion trap) mass spectrophotometer from Thermo Finnigan,
San Jose, CA, USA. Exact mass measurements are performed on a
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quadrupole time-of-flight mass spectrometer (Q-tof-2, Micromass,
Manchester, UK) equipped with a standard electrospray-ionization
(ESI) interface. Samples were infused in i-PrOH/H2O (1:1) at 3 μL/min.
Melting points are determined on a Barnstead IA 9200 and are
uncorrected. Precoated aluminum sheets (Fluka Silica gel/TLC-cards,
254 nm) were used for TLC. Column chromatography was performed
on ICN silica gel 63200, 60 Å. All final compounds possess a purity of
at least 95% (see Supporting Information) except derivatives 2a and 5c
(93 and 92% purity, respectively), as determined by analytical RP-HPLC
analysis on a XBridge column (C-18, 5 μm, 4.6 mm  150 mm) in
combination with a Waters 600 HPLC system, a Waters 717 plus
autosampler and aWaters 2996 photodiode array detector fromWaters,
Milford, Massachusetts, USA. Preparative HPLC purification was carried
out on the same instrument using a preparative XBridge column (C-18,
5 μm, 19 mm  150 mm) from Waters, Milford, Massachusetts, USA.
5-(2-Cyanovinyl)-20-deoxyuridine (8)3032. 5-Iodo-20-deoxyuri-
dine29 7a (250 mg, 0.71 mmol) was dissolved in anhydrous DMF
(10 mL), and the solution was flushed with nitrogen gas. To the solution
were added acrylonitrile (468 μL, 7.1 mmol), tributylamine (185 μL,
0.78 mmol), and tetrakis(triphenylphosphine)palladium(0) (81 mg,
0.07 mmol), and the reaction mixture was heated at 80 C for 9 h. The
solution was evaporated in vacuo and purified using silica gel column
chromatography (DCM/MeOH = 97:3f95:5) yielding compound 9
(116 mg, 59%). 1H NMR (300 MHz, DMSO-d6) δ 11.74 (s, 1H, NH),
8.35 (s, 1H,H-6), 7.23 (d, 1H, J= 16.3Hz, alkeneH), 6.52 (d, 1H, J= 16.3
Hz, alkene H), 6.09 (t, 1H, J = 6.2 Hz, H-10), 5.27 (s, 1H, OH), 5.13 (s,
1H,OH), 4.25 (m, 1H,H-30), 3.82 (m, 1H,H-40), 3.62 (ddd, 2H, J = 23.3,
12.0, 3.4 Hz, H-50), 2.16 (m, 2H, H-20). 13C NMR (75MHz, DMSO-d6)
δ 161.65, 149.01, 144.50, 144.35, 119.25, 107.73, 94.27, 87.74, 85.17,
69.68, 60.80, 40.15. HRMS (ESI) calcd for C12H13N3O5 278.0782 (M
Hþ); found 278.0773.
General Procedure for the Suzuki Reaction of 5-Iodonu-
cleosides 7ab with Various Boronic Acids. 5-Iodo-20-
deoxyuridine29 7a (250 mg, 0.71 mmol) (or 5-iodoracil 1-β-D-arabino-
furanoside 7b, 250 mg, 0.67 mmol) was dissolved in DMF (7.5 mL) and
H2O (3.75 mL). To the solution were added cesium fluoride (268 mg,
1.76 mmol) and a boronic acid (0.85 mmol), whereupon nitrogen gas
was passed through the solution for 5 min. Tetrakis(triphenylphos-
phine)palladium(0) (81 mg, 0.07 mmol) was added, and the reac-
tion mixture was heated at 60 C until the reaction was complete
(determined by TLC). The crude mixture was evaporated in vacuo and
purified using silica gel column chromatography (DCM/MeOH =
98:2f90:10), yielding title compounds 9ab.
5-(4-Fluorophenyl)-20-deoxyuridine (9a). This compound
was prepared according to the general procedure described above
starting from 7a using 4-fluorophenylboronic acid (119 mg), yielding
compound 9a (178 mg, 78%). 1H NMR (300 MHz, CD3OD) δ 8.31 (s,
1H, H-6), 7.59 (dd, 2H, J = 8.9, 5.4 Hz, ArH), 7.11 (t, 2H, J = 8.9 Hz,
ArH), 6.38 (t, 1H, J = 6.5 Hz, H-10), 4.46 (dd, 1H, J = 8.6, 4.9 Hz, H-30),
3.97 (q, 1H, J = 3.1 Hz, H-40), 3.80 (ddd, 2H, J = 25.7, 11.9, 2.9 Hz,
H-50), 2.34 (m, 2H, H-20). 13C NMR (75 MHz, CD3OD) δ 163.95,
161.93 (d, 1C, JCF = 185.4 Hz), 150.47, 138.35, 129.87 (d, 2C, JCF =
8.0 Hz), 129.14 (d, 1C, JCF = 3.3 Hz), 114.59 (d, 2C, JCF = 21.5 Hz),
113.67, 87.63, 85.40, 70.60, 61.08, 40.31. HRMS (ESI) calcd for
C15H15FN2O5 321.0892 (M  Hþ); found 321.0894.
5-(3-Methoxyphenyl)-20-deoxyuridine (9b). This compound
was prepared according to the general procedure described above
starting from 7a using 3-methoxyphenylboronic acid (129 mg), yielding
compound 9b (223 mg, 95%). 1HNMR (300MHz, CD3OD) δ 8.31 (s,
1H, H-6), 7.28 (t, 1H, J = 7.9 Hz, ArH), 7.17 (s, 1H, ArH), 7.13 (d, 1H,
J = 7.9 Hz, ArH), 6.89 (dd, 1H, J = 6.9, 2.2 Hz, ArH), 6.37 (t, 1H, J = 6.5
Hz, H-10), 4.46 (m, 1H, H-30), 3.97 (m, 1H, H-40), 3.82 (s, 3H, OCH3),
3.79 (ddd, 2H, J = 24.3, 12.0, 3.1 Hz, H-50), 2.35 (m, 2H, H-20). 13C
NMR (75 MHz, DMSO-d6) δ 162.47, 159.54, 150.36, 138.53, 135.00,
129.51, 120.66, 114.00, 113.72, 113.27, 88.09, 85.11, 70.77, 61.55, 55.51,
40.61. HRMS (ESI) calcd for C16H18N2O6 333.1092 (MHþ); found
333.1107.
30,50-di-O-Acetyl-20-deoxyuridine-5-heptynoic Acid (12a).
Compound 11a (1.68 g, 3.83mmol), Pd(PPh3)4 (433mg, 0.382mmol),
and CuI (147 mg, 0.764 mmol) were dissolved in anhydrous DMF
(20 mL) under an Ar atmosphere, and DIPEA (1.32 mL, 7.67 mmol)
and heptynoic acid (1.45 mL, 11.50 mmol) were then added. After being
stirred at rt for 22 h, the solvent was evaporated and coevaporated with
xylene. The residue was taken up in DCM/MeOH = 1:1 (40 mL),
BioRad XG-X8 (HCO3
-form) resin was added, and the mixture was
stirred at rt for 30 min. After filtration of the resin and evaporation of the
solvents, the crude residue was taken up in EtOAc (70 mL), and the
organic layer was washed with brine (3  70 mL), dried over MgSO4,
and evaporated. The residue was purified by silica gel column chroma-
tography (heptane/EtOAc = 2:3 containing 1% formic acid), and early
and late fractions were subjected to a second column using the same
eluent to yield compound 12a (783 mg, 47%) as an off-white solid. 1H
NMR (300 MHz, DMSO-d6) δ 12.05 (br s, 1H, COOH), 11.65 (br s,
1H, NH), 7.87 (s, 1H, H-6), 6.14 (t, 1H, J = 7.2 Hz, H-10), 5.18 (m, 1H,
H-30), 4.26 (d, 2H, J = 4.3 Hz, H-50), 4.19 (m, 1H, H-40), 2.542.28 (m,
2H, H-20), 2.39 (t, 2H, J = 6.9 Hz, R-CH2), 2.24 (t, 2H, J = 7.2 Hz,
CH2COOH), 2.08 (s, 3H, CH3), 2.06 (s, 3H, CH3), 1.651.45 (m, 4H,
2  CH2). 13C NMR (75 MHz, DMSO-d6) δ 174.32, 170.05, 161.59,
149.42, 142.36, 99.54, 93.30, 81.46, 73.81, 72.69, 63.56, 36.09, 33.15,
27.63, 23.83, 20.76, 20.55, 18.54. MS (ESI) calcd for C20H23N2O9
435.14 (M  Hþ), found 435.16.
20,30,50-tri-O-Acetyl-1-β-D-arabinofuranosyluracil-5-heptynoic
Acid (12b). Compound 11b (2 g, 4.03 mmol), Pd(PPh3)4 (455 mg,
0.403 mmol), and CuI (155 mg, 0.8 mmol) were dissolved in anhydrous
DMF (20 mL) under an Ar atmosphere, and DIPEA (1.39 mL, 8.08
mmol) and heptynoic acid (1.52 mL, 12.09 mmol) were then added.
After being stirred at rt overnight, the solvent was evaporated and
coevaporated with xylene. The residue was taken up in DCM/MeOH =
1:1 (40 mL), BioRad XG-X8 (HCO3
-form) resin was added, and the
mixture was stirred at rt for 30 min. After filtration of the resin and
evaporation of the solvents the crude residue was taken up in EtOAc
(80 mL), and the organic layer was washed with brine (3  80 mL),
dried over MgSO4, and evaporated. The residue was purified by silica gel
column chromatography (heptane/EtOAc = 2:3 containing 1% formic
acid), and early and late fractions were subjected to a second column
using the same eluent to yield compound 12b (1.04 g, 52%) as an off-
white solid. 1H NMR (300 MHz, DMSO-d6) δ 12.02 (br s, 1H,
COOH), 11.72 (br s, 1H, NH), 7.78 (s, 1H, H-6), 6.23 (d, 1H, J =
5.3 Hz, H-10), 5.41 (m, 1H, H-20), 5.25 (m, 1H, H-30), 4.35 (d, 2H, J =
4.3 Hz, H-50), 4.26 (m, 1H, H-40), 2.38 (t, 2H, J = 6.8 Hz, R-CH2), 2.24
(t, 2H, J = 7.2 Hz, CH2COOH), 2.09 (s, 6H, 2  CH3), 1.96 (s, 3H,
CH3), 1.631.47 (m, 4H, 2CH2). 13CNMR (75MHz, DMSO-d6) δ
174.25, 169.99, 169.69, 168.79, 161.34, 148.95, 142.83, 98. 81, 93.28,
82.97, 78.08, 74.90, 74. 36, 72.38, 62.54, 33.13, 27.57, 23.80, 20.56,
20.54, 20.13, 18.51. MS (ESI) calcd (M  Hþ) C22H25N2O11, 493.15;
found, 493.14.
30,50-di-O-Acetyl-20-deoxyuridine-5-(N-butyl)heptynamide
(13a). To a solution of compound 12a (350 mg, 0.802 mmol) and
HOBt (124 mg, 0.924 mmol) in anhydrous DCM (13 mL) under an Ar
atmosphere was added n-butylamine (92 μL, 0.924 mmol), and the
mixture was cooled to 0 C. DIC (125 μL, 0.807 mmol) was added, and
the reaction mixture was stirred at 0 C for 1 h and at rt for 5 h. The
solvent was evaporated and the residue taken up in EtOAc (25mL). The
organic layer was washed with satd NaHCO3 (3  20 mL), dried over
MgSO4, and evaporated. The residue was purified by silica gel column
chromatography (heptane/EtOAc = 1:3 containing 1% formic acid),
which gave compound 13a (321 mg, 81%) as an off-white solid. 1H
NMR (300MHz, DMSO-d6) δ 11.54 (br s, 1H, NH), 7.84 (s, 1H, H-6),
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7.61 (t, 1H, J = 5.3 Hz, amide NH), 6.14 (t, 1H, J = 7 Hz, H-10), 5.19 (m,
1H, H-30), 4.26 (d, 2H, J = 4.3 Hz, H-50), 4.19 (m, 1H, H-40), 3.03 (m,
2H, CH2NH), 2.532.28 (m, 2H, H-20), 2.37 (t, 2H, J = 6.9 Hz,
R-CH2), 2.112.03 (m, 8H, 2CH3 andCH2CO), 1.651.21 (m, 8H,
4  CH2), 0.87 (t, 3H, J = 7.2 Hz). 13C NMR (75 MHz, DMSO-d6) δ
171.59, 170.02 (2C), 161.60, 149.40, 142.34, 99.55, 93.40, 84.70, 81.43,
73.78, 72.63, 63.55, 38.04, 36.08, 34.82, 31.28, 27.73, 24.64, 20.75, 20.54,
19.56, 18.55, 13.65. MS (ESI) calcd for C24H33N3O8 492.23 (MþHþ),
514.22 (M þ Naþ), 1005.44 (2M þ Naþ); found 492.11, 514.10,
1004.86.
20,30,50-tri-O-Acetyl-1-β-D-arabinofuranosyluracil-5-(N-butyl)-
heptynamide (13b). To a solution of compound 12b (350mg, 0.712
mmol) and HOBt (110 mg, 0.82 mmol) in anhydrous DCM (12 mL)
under an Ar atmosphere was added n-butylamine (82 μL, 0.82 mmol),
and the mixture was cooled to 0 C. DIC (117 μL, 0.758 mmol) was
added, and the reaction mixture was stirred at 0 C for 1 h and at rt for
4 h. The solvent was evaporated and the residue taken up in EtOAc
(25 mL). The organic layer was washed with satd NaHCO3 (3 
20 mL), dried over MgSO4, and evaporated. The residue was purified by
silica gel column chromatography (heptane/EtOAc = 1:3 containing 1%
formic acid), which gave compound 13b (333 mg, 85%) as an off-white
solid. 1H NMR (300 MHz, DMSO-d6) δ 11.71 (br s, 1H, NH), 7.77 (s,
1H, H-6), 7.72 (t, 1H, J = 6.0 Hz, amide NH), 6.23 (d, 1H, J = 5.3 Hz,
H-10), 5.41 (t, 1H, J = 4.5 Hz, H-20), 5.26 (t, 1H, J = 4.6 Hz, H-30), 4.35
(m, 2H, H-50), 4.25 (m, 1H, H-40), 3.02 (m, 2H, CH2NH), 2.37 (t, 2H,
J = 6.9 Hz, R-CH2), 2.112.03 (m, 8H, 2CH3 and CH2CO), 1.96 (s,
3H, CH3), 1.631.20 (m, 8H, 4 CH2), 0.86 (t, 3H, J = 7.1 Hz, CH3).
13C NMR (75 MHz, DMSO-d6) δ 171.57, 169.97, 169.69, 161.35,
148.94, 142.80, 98.83, 93.40, 82.96, 78.03, 74.86, 74.36, 72.31, 62.53,
38.02, 34.80, 31.27, 27.69, 24.62, 20.53, 20.11, 19.54, 18.52, 13.64. MS
(ESI) calcd for C26H35N3O10 550.24 (M þ Hþ), 572.22 (M þ Naþ),
1121.45 (2M þ Naþ); found 550.10, 572.19, 1120.88.
20-Deoxyuridine-5-(N-butyl)heptynamide (14a). Com-
pound 13a (276 mg, 0.562 mmol) was dissolved in dry MeOH
(8 mL), NaOMe (30%-solution in MeOH, 152 μL, 0.8 mmol) was
added, and the reaction mixture was stirred for 1 h at rt under an Ar
atmosphere. The solution was neutralized with Dowex 50WX-8 resin
(Hþ-form), and the resin was filtered off and washed with MeOH. After
evaporation of the filtrate the residue was purified by silica gel column
chromatography (EtOAc/MeOH = 98:2), which yielded compound
14a (204 mg, 89%) as an off-white solid. 1H NMR (300 MHz, DMSO-
d6) δ 11.55 (br s, 1H, NH), 8.15 (s, 1H, H-6), 7.76 (t, 1H, J = 5.4 Hz,
amide NH), 6.11 (t, 1H, J = 6.6 Hz, H-10), 5.24 (d, 1H, J = 4.2 Hz, OH),
5.14 (t, 1H, J = 4.8 Hz, OH), 4.23 (m, 1H, H-30), 3.79 (m, 1H, H-40),
3.59 (m, 2H, H-50), 3.02 (m, 2H, CH2NH), 2.36 (t, 2H, J = 6.9 Hz,
R-CH2), 2.132.05 (m, 4H,H-20 andCH2CO), 1.641.19 (m, 8H, 4
CH2), 0.86 (t, 3H, J = 7.2 Hz, CH3).
13C NMR (75 MHz, DMSO-d6) δ
171.81, 161.79, 149.48, 142.81, 99.00, 92.99, 87.53, 84.59, 73.00, 70.13,
60.97, 38.08, 34.86, 31.27, 27.74, 24.62, 19.57, 18.59, 13.67. MS (ESI)
calcd for C20H29N3O6 408.21 (M þ Hþ), 430.20 (M þ Naþ), 837.40
(2M þ Naþ); found 408.12, 430.12, 837.04. HRMS (ESI) calcd for
C20H29N3O6 446.1693 (M þ Kþ); found 446.1674.
1-β-D-Arabinofuranosyluracil-5-(N-butyl)heptynamide (14b).
Compound 13b (303 mg, 0.551 mmol) was dissolved in dry MeOH
(8 mL), NaOMe (30%-solution in MeOH, 152 μL, 0.8 mmol) was
added, and the reaction mixture was stirred for 1 h at rt under an Ar
atmosphere. The solution was neutralized with Dowex 50WX-8 resin
(Hþ-form), and the resin was filtered off and washed with MeOH. After
evaporation of the filtrate, the residue was purified by silica gel column
chromatography (EtOAc/MeOH = 95:5), which yielded compound
14b (206 mg, 88%) as an off-white solid. 1H NMR (300 MHz, DMSO-
d6) δ 11.55 (br s, 1H, NH), 7.84 (s, 1H, H-6), 7.75 (t, 1H, J = 5.4 Hz,
amide NH), 5.96 (d, 1H, J = 4.4 Hz, H-10), 5.60 (d, 1H, J = 5.1 Hz, OH),
5.47 (br s, 1H, OH), 5.15 (br s, 1H, OH), 4.00 (m, 1H, H-20), 3.90 (m,
1H, H-30), 3.74 (m, 1H, H-40), 3.61 (m, 2H, H-50), 3.02 (m, 2H,
CH2NH), 2.36 (t, 2H, J = 6.9 Hz, R-CH2), 2.07 (t, 2H, J = 7.3 Hz,
CH2CO), 1.641.20 (m, 8H, 4 CH2), 0.86 (t, 3H, J = 7.2 Hz, CH3).
13C NMR (75 MHz, DMSO-d6) δ 171.77, 161.94, 149.44, 144.26,
97.45, 92.67, 85.29, 84.72, 75.21, 75.15, 73.06, 60.42, 38.07, 34.86, 31.27,
27.77, 24.65, 19.57, 18.57, 13.67. MS (ESI) calcd for C20H29N3O7
424.21 (M þ Hþ), 446.19 (M þ Naþ), 869.39 (2M þ Naþ); found
424.06, 446.09, 868.96. HRMS (ESI) calcd for C20H29N3O7 424.2078
(M þ Hþ), 446.1898 (M þ Naþ), 462.1642 (M þ Kþ); found
424.2080, 446.1880, 462.1578.
N-(Prop-2-ynyl)heptane-1-sulfonamide (16). Sodium 1-hep-
tanesulfonate (1 g, 4.95 mmol) was refluxed in neat thionyl chloride
overnight under an Ar atmosphere. The mixture was allowed to cool to
rt, and then the volatiles were removed in vacuo and the residue was
dissolved in dry DCM (15 mL) under an Ar atmosphere. A mixture of
NEt3 (705 μL, 5.01 mmol) and propargylamine (315 μL, 4.91 mmol)
were subsequently added dropwise at 0 C. The ice bath was removed,
and the reaction mixture was stirred at rt overnight, diluted with DCM
(25 mL), washed with H2O, satd NaHCO3, and again H2O (40 mL
each), dried over MgSO4, and evaporated to yield sulfonamide 16
(535 mg, 50%) as a red oil. This product was used in the Sonogashira
coupling step without further purification. 1HNMR (300MHz, CDCl3)
δ 4.53 (m, 1H, NH), 3.95 (m, 2H,R-CH2), 3.14 (m, 2H, CH2SO2), 2.35
(t, 1H, J = 2.5 Hz, acetylenic H), 1.85 (m, 2H, CH2CH2SO2), 1.481.19
(m, 8H, 4  CH2), 0.89 (t, 3H, J = 6.9 Hz, CH3) 13C NMR (75 MHz,
CDCl3) δ 79.19, 73.09, 53.73, 32.76, 31.61, 28.87, 28.34, 23.74, 22.66,
14.15. MS (ESI) calcd for C10H19NO2S 216.11 (M  Hþ); found
215.70.
1-Hexyl-3-(prop-2-ynyl)urea (17). Propargylamine (500 μL,
7.80 mmol) was dissolved in anhydrous DCM (20 mL) under an Ar
atmosphere, and the resulting yellow solution was cooled to 0 C. Hexyl
isocyanate (995 mg, 7.82 mmol) dissolved in 10 mL of anhydrous DCM
was added drop- to portionwise, the ice bath was removed, and the
reaction mixture was stirred at rt for 45 min. The solvent was evaporated
to yield compound 17 (1.39 g, 98%) as an off-white solid, which was
used in the following step without further purification. 1H NMR (300
MHz, CDCl3) δ 5.51 (br s, 1H, NH), 5.32 (br s, 1H, NH), 3.97 (m, 2H,
R-CH2), 3.16 (m, 2H, CH2NH), 2.20 (t, 1H, J = 2.5 Hz, acetylenic H),
1.48 (m, 2H, CH2CH2NH), 1.29 (m, 6H, 3CH2), 0.88 (t, 3H, J = 6.7
Hz, CH3).
13C NMR (75 MHz, CDCl3) δ 158.43, 81.15, 70.91, 40.65,
31.69, 30.33, 30.12, 26.73, 22.71, 14.14. MS (ESI) calcd for C10H18N2O
183.15 (M þ Hþ); found 183.09.
N-(3-(5-(20-Deoxyuridine))prop-2-ynyl)octanamide (18a).
Compound 11a (400 mg, 0.913 mmol), Pd(PPh3)4 (103 mg, 0.091
mmol), and CuI (35 mg, 0.182 mmol) were dissolved in anhydrous
DMF (5mL) under an Ar atmosphere, andDIPEA (313 μL, 1.82mmol)
and acetylene 15a (496 mg, 2.74 mmol) were then added. After being
stirred at rt for 12 h, the solvent was evaporated and coevaporated with
xylene. The residue was taken up in DCM/MeOH = 1:1 (20 mL),
BioRad XG-X8 (HCO3
-form) resin was added, and the mixture was
stirred at rt for 30 min. After filtration of the resin and evaporation of the
solvents, the crude residue was taken up in EtOAc (30 mL) and the
organic layer was washed with brine (3  30 mL), dried over MgSO4,
and evaporated. The residue was purified by silica gel column chroma-
tography (cyclohexane/EtOAc = 1:1 containing 1% formic acid), and
the obtained intermediate was dissolved in dry MeOH (14 mL).
NaOMe (30%-solution in MeOH, 265 μL, 1.4 mmol) was added, and
the reaction mixture was stirred for 1 h at rt under an Ar atmosphere. The
solutionwas neutralizedwithDowex 50WX-8 resin (Hþ-form), and the resin
was filtered off and washed with MeOH. After evaporation of the filtrate, the
residue was purified by silica gel column chromatography (EtOAc/MeOH=
98:2 containing 0.5% formic acid), which yielded compound 18a (251 mg,
68% over 2 steps) as an off-white solid. 1H NMR (300 MHz, DMSO-d6) δ
11.61 (br s, 1H, NH), 8.29 (t, 1H, J = 5.4Hz, amideNH), 8.16 (s, 1H, H-6),
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6.11 (t, 1H, J = 6.7 Hz, H-10), 5.25 (d, 1H, J = 3.9 Hz, OH), 5.10 (t, 1H,
J = 4.7 Hz, OH), 4.22 (m, 1H, H-30), 4.06 (d, 2H, J = 5.4 Hz, R-CH2),
3.79 (m, 1H, H-40), 3.633.53 (m, 2H, H-50), 2.10 (m, 4H, H-20 and
CH2CO), 1.48 (m, 2H, CH2CH2CO), 1.24 (m, 8H, 4  CH2), 0.85
(t, 3H, J = 7.0 Hz, CH3).
13C NMR (75 MHz, DMSO-d6) δ 171.83,
161.59, 149.41, 143.60, 98.15, 89.78, 87.62, 84.70, 74.19, 70.24, 61.03,
35.07, 31.13, 28.60, 28.47, 28.41, 25.11, 22.03, 13.92. MS (ESI) calcd
for C20H29N3O6 408.21 (M þ Hþ), 430.20 (M þ Naþ), 837.40
(2M þ Naþ); found 408.09, 430.05, 836.95. HRMS (ESI) calcd for
C20H29N3O6 446.1693 (M þ Kþ); found 446.1670.
N-(3-(5-(20-Deoxyuridine))prop-2-ynyl)hexanamide (18b).
Compound 11a (400 mg, 0.913 mmol), Pd(PPh3)4 (103 mg, 0.091
mmol), and CuI (35 mg, 0.182 mmol) were dissolved in anhydrous
DMF (5mL) under an Ar atmosphere, andDIPEA (313 μL, 1.82mmol)
and acetylene 15b (420 mg, 2.74 mmol) were then added. After being
stirred at rt for 14 h, the solvent was evaporated and coevaporated with
xylene. The residue was taken up in DCM/MeOH = 1:1 (10 mL),
BioRad XG-X8 (HCO3
-form) resin was added, and the mixture was
stirred at rt for 30 min. After filtration of the resin and evaporation of the
solvents, the crude residue was taken up in EtOAc (30 mL), and the
organic layer was washed with brine (3  30 mL), dried over MgSO4,
and evaporated. The residue was purified by silica gel column chroma-
tography (heptane/EtOAc = 2:3 containing 1% formic acid), and the
obtained intermediate was dissolved in dry MeOH (14 mL). NaOMe
(30% solution inMeOH, 265 μL, 1.4mmol) was added, and the reaction
mixture was stirred for 1 h at rt under an Ar atmosphere. The solution
was neutralized with Dowex 50WX-8 resin (Hþ-form), and the resin was
filtered off and washed with MeOH. After evaporation of the filtrate, the
residue was purified by silica gel column chromatography (EtOAc/
MeOH = 98:2 containing 1% formic acid), which yielded compound
18b (209 mg, 60% over 2 steps) as an off-white solid. 1H NMR
(300 MHz, CDCl3:MeOD = 5:2) δ 8.33 (s, 1H, H-6), 6.25 (t, 1H, J =
6.5 Hz, H-10), 4.43 (m, 1H, H-30), 4.13 (br s, 2H, R-CH2), 3.98 (m, 1H,
H-40), 3.87 (dd, 1H, J = 12, 2.9 Hz, H-50), 3.77 (dd, 1H, J = 12, 2.9 Hz,
H-50), 2.402.34 (m, 1H, H-20), 2.232.14 (m, 3H, H-20 andCH2CO),
1.63 (m, 2H, CH2CH2CO), 1.33 (m, 4H, 2  CH2), 0.90 (t, 3H, J = 7
Hz, CH3).
13C NMR (75 MHz, CDCl3:MeOD = 5:2) δ 174.31, 163.12,
149.54, 143.91, 98.83, 88.98, 87.52, 85.71, 73.85, 70.36, 61.19, 40.79,
35.93, 31.17, 29.53, 25.10, 22.09, 13.48.MS (ESI) calcd for C18H25N3O6
380.18 (M þ Hþ), 402.16 (M þ Naþ), 781.33 (2M þ Naþ); found
379.72, 401.67, 780.43. HRMS (ESI) calcd for C18H25N3O6 402.1636
(M þ Naþ), 418.1380 (M þ Kþ); found 402.1656, 418.1379.
N-(3-(5-(20-Deoxyuridine))prop-2-ynyl)butanamide (18c).
Compound 11a (400 mg, 0.913 mmol), Pd(PPh3)4 (103 mg, 0.091
mmol), and CuI (35 mg, 0.182 mmol) were dissolved in anhydrous
DMF (4mL) under an Ar atmosphere, andDIPEA (313 μL, 1.82mmol)
and then acetylene 15c (343 mg, 2.74 mmol, dissolved in 1 mL
anhydrous DMF) were then added. After being stirred at rt for 18 h,
the solvent was evaporated and coevaporated with xylene. The residue
was taken up in DCM/MeOH= 1:1 (10mL), BioRad XG-X8 (HCO3
-
form) resin was added, and the mixture was stirred at rt for 30 min. After
filtration of the resin and evaporation of the solvents, the crude residue
was taken up in EtOAc (30 mL), and the organic layer was washed with
brine (3 30 mL), dried over MgSO4, and evaporated. The residue was
purified by silica gel column chromatography (heptane/EtOAc =
1:2f1:3 each containing 1% formic acid), and the obtained intermedi-
ate was dissolved in dry MeOH (14 mL). NaOMe (30% solution in
MeOH, 265 μL, 1.4 mmol) was added, and the reaction mixture was
stirred for 1 h at rt under an Ar atmosphere. The solution was neutralized
with Dowex 50WX-8 resin (Hþ-form), and the resin was filtered off and
washed with MeOH. After evaporation of the filtrate, the residue was
purified by silica gel column chromatography (EtOAc/MeOH = 98:2
containing 1% formic acid), which yielded compound 18c (193mg, 60%
over 2 steps) as an off-white solid. 1HNMR (300MHz, CDCl3:MeOD=
5:2) δ 8.37 (s, 1H, H-6), 6.26 (t, 1H, J = 6.4 Hz, H-10), 4.44 (m, 1H,
H-30), 4.14 (s, 2H,R-CH2), 3.99 (m, 1H, H-40), 3.89 (dd, 1H, J = 12, 2.6
Hz, H-50), 3.78 (dd, 1H, J = 12, 2.6 Hz, H-50), 2.412.34 (m, 1H, H-20),
2.232.16 (m, 3H,H-20 andCH2CO), 1.66 (m, 2H, CH2CH2CO), 0.96
(t, 3H, J = 7.4 Hz, CH3).
13C NMR (75 MHz, CDCl3:MeOD = 5:2) δ
174.14, 163.09, 149.53, 143.90, 98.82, 88.97, 87.51, 85.70, 73.82, 70.35,
61.19, 40.77, 37.79, 29.50, 18.81, 13.23.MS (ESI) calcd for C16H21N3O6
352.15 (M þ Hþ), 374.13 (M þ Naþ), 725.28 (2M þ Naþ); found
351.74, 373.68, 724.37. HRMS (ESI) calcd for C16H21N3O6 390.1067
(M þ Kþ); found 390.1058.
2-Phenyl-N-(3-(5-(20-deoxyuridine))prop-2-ynyl)acetamide
(18d). Compound 11a (400 mg, 0.913 mmol), Pd(PPh3)4 (103 mg,
0.091 mmol), and CuI (35 mg, 0.182 mmol) were dissolved in anhy-
drous DMF (5 mL) under an Ar atmosphere, and DIPEA (313 μL,
1.82 mmol) and then acetylene 15d (474 mg, 2.74 mmol) were then
added. After being stirred at rt for 14 h, the solvent was evaporated and
coevaporated with xylene. The residue was taken up in DCM:MeOH =
1:1 (10 mL), BioRad XG-X8 (HCO3
-form) resin was added, and the
mixture was stirred at rt for 30 min. After filtration of the resin and
evaporation of the solvents, the crude residue was taken up in EtOAc
(30 mL), and the organic layer was washed with brine (3  30 mL),
dried over MgSO4, and evaporated. The residue was purified by silica gel
column chromatography (heptane:EtOAc = 1:2f1:3 each containing
1% formic acid) and the obtained intermediate was dissolved in dry
MeOH (14 mL). NaOMe (30% solution in MeOH, 265 μL, 1.4 mmol)
was added, and the reaction mixture was stirred for 1 h at rt under an Ar
atmosphere. The solution was neutralized with Dowex 50WX-8 resin
(Hþ-form), the resin was filtered off and washed with MeOH. After
evaporation of the filtrate, the residue was purified by silica gel column
chromatography (EtOAc:MeOH = 98:2 containing 1% formic acid),
which yielded compound 18d (231mg, 63% over 2 steps) as an off-white
solid. 1H NMR (300 MHz, MeOD) δ 8.29 (s, 1H, H-6), 7.357.19 (m,
5H, ArH), 6.23 (t, 1H, J = 6.6 Hz, H-10), 4.38 (m, 1H, H-30), 4.14 (s, 2H,
R-CH2), 3.94 (m, 1H, H-40), 3.823.68 (ddd, 2H, J = 24.5, 12, 3.4 Hz,
H-50), 3.52 (s, 2H, CH2Ph), 2.342.15 (m, 2H, H-20). 13C NMR
(75 MHz, MeOD) δ 173.63, 164.53, 151.14, 145.44, 136.64, 130.13
(2C), 129.58 (2C), 127.93, 99.91, 89.92, 89.17, 87.06, 75.25, 72.05,
62.62, 43.63, 41.70, 30.63. MS (ESI) calcd for C20H21N3O6 400.15
(M þ Hþ), 422.13 (M þ Naþ), 821.28 (2M þ Naþ); found 399.77,
421.63, 821.55. HRMS (ESI) calcd for C20H21N3O6 438.1067 (Mþ Kþ);
found 438.1040.
2-Phenyl-N-(3-(5-(50-O-acetyl-20-deoxyuridine))prop-2-ynyl)-
acetamide (23). Compound 22 (200 mg, 0.505 mmol), Pd(PPh3)4
(58 mg, 0.051 mmol), and CuI (20 mg, 0.104 mmol) were dissolved in
anhydrous DMF (3 mL) under an Ar atmosphere, and DIPEA (174 μL,
1.01 mmol) and then acetylene 15d (262 mg, 1.51 mmol) were then
added. After being stirred at rt for 16 h, the solvent was evaporated and
coevaporated with xylene. The residue was taken up in DCM/MeOH =
1:1 (10 mL), BioRad XG-X8 (HCO3
-form) resin was added, and the
mixture was stirred at rt for 30 min. After filtration of the resin and
evaporation of the solvents, the crude residue was purified by a first
column of silica gel (DCM/MeOH = 98:2f97:3 each containing 1%
formic acid), and the obtained product was subjected to a second short
column of silica gel (DCM/MeOH = 95:5 containing 1% formic acid),
which yielded compound 23 (118 mg, 53%) as an off-white solid. 1H
NMR (300MHz, CDCl3) δ 9.97 (br s, 1H, NH), 8.23 (s, 1H, H-6), 7.27
(m, 5H, ArH), 6.88 (t, 1H, J = 5 Hz, amide NH), 6.24 (t, 1H, J = 6.9 Hz,
H-10), 5.32 (m, 1H, H-30), 4.12 (m, 3H, R-CH2 and H-40), 3.86 (m, 2H,
H-50), 3.57 (s, 2H, CH2CO), 2.47 (m, 2H, H-20), 2.08 (s, 3H, CH3).
13C
NMR (75 MHz, CDCl3) δ 172.14, 170.82, 162.69, 149.58, 144.58,
134.61, 129.54 (2C), 128.95 (2C), 127.40, 99.45, 89.65, 86.08, 85.82,
75.05, 74.26, 62.20, 43.20, 38.32, 30.44, 21.11. MS (ESI) calcd for
C22H23N3O7 442.16 (M þ Hþ), 464.14 (M þ Naþ), 905.30 (2M þ
Naþ); found 441.68, 463.65, 904.37.
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N-(3-(5-(30-O-Acetyl-20-deoxyuridine))prop-2-ynyl)heptane-
1-sulfonamide (24). Compound 22 (325 mg, 0.82 mmol), Pd-
(PPh3)4 (91 mg, 0.082 mmol), and CuI (32 mg, 0.164 mmol) were
dissolved in anhydrous DMF (4 mL) under an Ar atmosphere, and
DIPEA (283 μL, 1.64 mmol) and then acetylene 16 (535 mg,
2.46 mmol) dissolved in anhydrous DMF (1 mL) were added. After being
stirred at rt overnight, the solvent was evaporated and coevaporated with
xylene. The residue was taken up in DCM/MeOH = 1:1 (10 mL),
BioRad XG-X8 (HCO3
-form) resin was added, and the mixture was
stirred at rt for 30 min. After filtration of the resin and evaporation of the
solvents, the crude residue was purified by a first column of silica gel
(heptane/EtOAc = 1:1 containing 1% formic acid) and the obtained
product was subjected to a second short column of silica gel (DCM/
acetone =85:15 containing 1% formic acid), which yielded compound
24 (225mg, 57%) as an off-white solid. 1HNMR (300MHz, DMSO-d6)
δ 11.70 (br s, 1H, NH), 8.24 (s, 1H, H-6), 7.64 (br s, 1H, amide NH),
6.14 (t, 1H, J = 7.1 Hz, H-10), 5.29 (br s, 1H, OH), 5.22 (m, 1H, H-30),
4.04 (br m, 1H, H-40), 3.98 (d, 2H, J = 5.2 Hz, R-CH2), 3.64 (d, 2H, J =
2.5 Hz, H-50), 3.13 (m, 2H, CH2SO2), 2.29 (m, 2H, H-20), 2.06 (s, 3H,
CH3), 1.65 (m, 2H, CH2CH2SO2), 1.491.12 (m, 8H, 4 CH2), 0.82
(t, 3H, J = 7.0 Hz, CH3)
13C NMR (75 MHz, DMSO-d6) δ 169.98,
161.44, 149.38, 143.49, 98.21, 88.97, 85.07, 84.57, 75.80, 74.62, 61.16,
52.15, 37.30, 32.38, 30.97, 28.26, 27.47, 23.20, 21.92, 20.80, 13.85 MS
(ESI) calcd for C21H31N3O8S 486.19 (M þ Hþ), 508.17 (M þ Naþ);
found 486.3, 508.2.
1-Hexyl-(3-(5-(30-O-acetyl-20-deoxyuridine))prop-2-ynyl)-
urea (25). Compound 22 (300 mg, 0.756 mmol), Pd(PPh3)4 (84 mg,
0.075 mmol), and CuI (29 mg, 0.151 mmol) were dissolved in
anhydrous DMF (5 mL) under an Ar atmosphere, and DIPEA (261
μL, 1.52mmol) and then acetylene 17 (415mg, 2.27mmol) were added.
After being stirred at rt overnight, the solvent was evaporated and
coevaporated with xylene. The residue was taken up in DCM/MeOH =
1:1 (10 mL), BioRad XG-X8 (HCO3
-form) resin was added, and the
mixture was stirred at rt for 30 min. After filtration of the resin and
evaporation of the solvents, the crude residue was purified by a first
column of silica gel (heptane/EtOAc = 1:2f1:3f1:4 each containing
1% formic acid), and the obtained product was subjected to a second
short column of silica gel (DCM/acetone = 80:20f75:25 each contain-
ing 1% formic acid), which yielded compound 25 (259 mg) as an oil
containing substantial amounts of impurities and was therefore used in
the phosphorylation step without any further purification.
General Procedure A33,46 for the Phosphorylation of
5-Substituted Derivatives 8, 9ab, 18bc. An unprotected
5-substituted derivative (1 equiv) was dissolved in PO(OMe)3/CH3CN =
1:1, and dry pyridine (4.8 equiv) and H2O (2.8 equiv) were added and
the resulting solution was cooled to 0 C. POCl3 (4.4 equiv) was added
in one portion, and the reaction mixture was stirred at 0 C for 3 h. The
reaction mixture was poured into ice/H2O and brought to pH 89 with
NH4OH, and then the volatiles were removed in vacuo and the residue
was purified by silica gel column chromatography using a gradient of
2-propanol/water/NH4OH. The phosphates isolated after lyophilization
were further purified by preparative RP-HPLC (C18, 5 μM, 19 mm
150 mm) using a gradient of acetonitrile and TEAB (410 mM),
yielding analytically pure compounds. Next, the phosphates were
subjected to ion exchange (Dowex 50 WX-8, Naþ) and lyophilized,
yielding the corresponding disodium salts.
General Procedure B37,38 for the Phosphorylation of
5-Substituted Derivatives 10ab, 14ab, 18a. To a solution
of an unprotected 5-substituted derivative (1 equiv) and proton sponge
(1.53 equiv) in trimethyl phosphate was added POCl3 (1.53 equiv)
in one portion at 0 C, and the reaction mixture was stirred at 0 C for
23 h. The reaction mixture was poured into ice/H2O and brought to
pH 89 with NH4OH or 1 M NaOH, and then the volatiles were
removed in vacuo and the residue was purified by silica gel column
chromatography using a gradient of 2-propanol/water/NH4OH. The
phosphates isolated after lyophilization were further purified by pre-
parative RP-HPLC (C18, 5 μM, 19 mm  150 mm) using a gradient
of acetonitrile and TEAB (430 mM), yielding analytically pure
compounds. Next, the phosphates were subjected to ion exchange
(Dowex 50 WX-8, Naþ) and lyophilized, yielding the corresponding
disodium salts.
5-(2-Cyanovinyl)-20deoxyuridine-50-monophosphate (1).
This compound was prepared according to the general procedure A de-
scribed above. The reaction mixture was worked up as described above
including silica gel column chromatography (2-propanol/NH4OH/
H2O = 90:5:5f75:15:15) and RP-HPLC (10 mM aq TEAB/CH3CN=
95:5f80:20, 16 mL/min), yielding title compound 1 (49 mg, 49%) as
a white solid. 1H NMR (500 MHz, D2O) δ 8.15 (s, 1H, H-6), 7.35 (d,
1H, J = 16.4 Hz, vinylic H), 6.52 (d, 1H, J = 16.4 Hz, vinylic H), 6.30 (t,
1H, J = 6.8 Hz, H-10), 4.53 (m, 1H, H-30), 4.12 (q, 1H, J = 3.6 Hz, H-40),
3.92 (d, 2H, J = 4.4 Hz, H-50), 2.35 (m, 2H, H-20). 13CNMR (125MHz,
D2O) δ 161.82, 156.10, 146.12, 143.99, 120.61, 109.91, 94.10, 86.08 (d,
1C, JCP = 8.3 Hz), 85.71, 71.03, 63.49, 39.17.
31P NMR (121 MHz,
D2O) δ 3.97. MS (ESI) calcd for C12H14N3O8P 358.0446 (M  Hþ);
found 358.0431.
5-(4-Fluorophenyl)-20-deoxyuridine-50-monophosphate
(2a). This compound was prepared according to the general procedure
A described above. The reaction mixture was worked up as described
above, including silica gel column chromatography (2-propanol/
NH4OH/H2O = 90:5:5f75:15:15) and RP-HPLC (10 mM aq
TEAB:CH3CN = 95:5f80:20, 16 mL/min), yielding title compound
2a (53 mg, 24%) as a white solid. 1H NMR (500 MHz, D2O) δ 7.84 (s,
1H, H-6), 7.45 (dd, 2H, J = 8.6, 5.5 Hz, ArH), 7.14 (t, 2H, J = 8.9 Hz,
ArH), 6.33 (t, 1H, J = 7.0 Hz, H-10), 4.52 (m, 1H, H-30), 4.16 (m, 1H,
H-40), 4.04 (m, 2H, H-50), 2.39 (m, 2H, H-20). 13C NMR (125 MHz,
D2O) δ 164.74, 162.33 (d, 1C, JCF = 244.5 Hz), 151.19, 138.48, 130.60
(d, 2C, JCF = 8.4 Hz), 127.76 (d, 1C, JCF = 2.2 Hz), 115.31 (d, 2C, JCF =
21.8 Hz), 115.11, 85.55 (d, 1C, JCP = 12.0 Hz), 85.45, 70.95, 64.83 (d,
1C, JCP = 4.5 Hz), 38.76.
31P NMR (121MHz, D2O) δ 0.015. MS (ESI)
calcd for C15H16FN2O8P 401.0555 (M  Hþ); found 401.0569.
5-(3-Methoxyphenyl)-20-deoxyuridine-50-monophosphate
(2b). This compound was prepared according to the general procedure
A described above. The reaction mixture was worked up as described
above, including silica gel column chromatography (2-propanol/
NH4OH/H2O = 90:5:5f75:15:15) and RP-HPLC (10 mM aq
TEAB/CH3CN = 95:5f 80:20, 16 mL/min), yielding title compound
2b (102 mg, 37%) as a white solid. 1HNMR (300MHz, D2O) δ 7.65 (s,
1H, H-6), 7.26 (t, 1H, J = 8.2 Hz, ArH), 6.94 (m, 2H, ArH), 6.87 (dd,
1H, J = 8.2, 1.6 Hz, ArH), 6.16 (t, 1H, J = 6.8 Hz, H-10), 4.43 (m, 1H,
H-30), 4.09 (m, 1H, H-40), 4.03 (m, 2H, H-50), 3.73 (s, 3H, OCH3), 2.29
(m, 2H, H-20). 13C NMR (75 MHz, D2O) δ 163.93, 158.35, 150.65,
138.23, 132.91, 129.59, 120.90, 114.86, 113.78, 113.46, 85.60, 85.06 (d,
1C, JCP = 8.2 Hz), 70.63, 65.00 (d, 1C, JCP = 4.9 Hz), 55.02, 38.55.
31P
NMR (121 MHz, D2O) δ 0.014. MS (ESI) calcd for C16H19N2O9P
413.0755 (M  Hþ); found 413.0731.
5-Dodecynyl-20-deoxyuridine-50-monophosphate (3a). This
compound was prepared according to the general procedure B described
above. The following amounts of starting material and reagents were
employed: compound 10a (500 mg, 1.29 mmol), POCl3 (181 μL, 1.94
mmol), and proton sponge (416 mg, 1.94 mmol) in 5 mL of PO(OMe)3.
The reactionmixture was stirred at 0 C for 2 h and worked up as described
above, including silica gel column chromatography (2-propanol/NH4OH/
H2O= 77.5:15:2.5f70:20:5) and RP-HPLC (4mM aq TEAB/CH3CN=
73:27f60:40, 16mL/min), yielding title compound 3a (159mg, 24%) as a
white solid;mp >151 C (dec). 1HNMR (300MHz, DMSO-d6) δ 7.77 (s,
1H, H-6), 6.08 (t, 1H, J = 6.9 Hz, H-10), 4.27 (m, 1H, H-30), 3.88 (m, 1H,
H-40), 3.79 (m, 2H, H-50), 2.35 (t, 2H, J = 7.1 Hz, R-CH2), 2.211.99
(m, 2H, H-20), 1.48 (m, 2H, β-CH2), 1.24 (m, 14H, 7  CH2), 0.85
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(t, 3H, J= 6.7Hz, CH3).
13CNMR(75MHz,DMSO-d6) δ 161.72, 149.47,
142.25, 99.40, 93.68, 86.10 (d, 1C, JCP = 6.3 Hz), 84.43, 72.54, 70.74, 64.11
(d, 1C, JCP = 4.8 Hz), 39.40, 31.30, 28.98, 28.71, 28.56, 28.38, 28.19, 22.09,
18.88, 13.95. 31P NMR (121 MHz, DMSO-d6) δ 0.40. HRMS (ESI) calcd
for C21H32N2O8P 471.1902 (M  Hþ); found 471.1884.
1-β-D-Arabinofuranosyl-5-dodecynyluracil-50-monopho-
sphate (3b). This compound was prepared according to the general
procedure B described above. The following amounts of starting
material and reagents were employed: compound 10b (500 mg, 1.22
mmol), POCl3 (171 μL, 1.83 mmol), and proton sponge (392 mg, 1.83
mmol) in 5 mL of PO(OMe)3. The reaction mixture was stirred at 0 C
for 2 h and worked up as described above, including silica gel column
chromatography (2-propanol/NH4OH/H2O = 74:17.5:3.5f70:20:5,
16 mL/min) and RP-HPLC (4 mM aq TEAB/CH3CN = 75:25f
60:40), yielding title compound 3b (214 mg, 33%) as a white solid; mp
>159 C (dec). 1H NMR (300 MHz, DMSO-d6) δ 11.59 (br s, 1H,
NH), 7.57 (s, 1H, H-6), 5.94 (d, 1H, J = 3.6 Hz, H-10), 4.71 (br s, 2H,
20OH and 30OH), 4.04 (m, 1H, H-20), 3.92 (br m, 3H, H-30 and
H-50), 3.80 (m, 1H, H-40), 2.35 (t, 2H, J = 7.1 Hz, R-CH2), 1.48 (m, 2H,
β-CH2), 1.24 (m, 14H, 7  CH2), 0.85 (t, 3H, J = 6.7 Hz, CH3). 13C
NMR (75 MHz, DMSO-d6) δ 161.90, 149.40, 144.05, 97.47, 93.20,
85.73, 84.07, 76.34, 74.87, 72.72, 63.91, 31.32, 28.99, 28.72, 28.57, 28.42,
28.25, 22.11, 18.83, 13.97. 31P NMR (121 MHz, DMSO-d6) δ 1.70.
HRMS (ESI) calcd for C21H32N2O9P 487.1851 (M  Hþ); found
487.1847.
20-Deoxyuridine-5-(N-butyl)heptynamide-50-monopho-
sphate (4a). This compound was prepared according to the general
procedure B described above. The following amounts of starting
material and reagents were employed: compound 14a (154 mg, 0.378
mmol), POCl3 (53 μL, 0.567mmol), and proton sponge (121mg, 0.567
mmol) in 1.5 mL of PO(OMe)3. The reaction mixture was stirred at
0 C for 3 h and worked up as described above, including silica gel
column chromatography (2-propanol/NH4OH/H2O = 77.5:15:2.5f
74:17:3.5) and RP-HPLC (4 mM aq TEAB/CH3CN = 85:15, isocratic,
16 mL/min), yielding title compound 4a (52 mg, 26%) as a white solid;
mp >192 C (dec). 1H NMR (500 MHz, DMSO-d6) δ 11.58 (br s, 1H,
NH), 8.20 (br s, 1H, amide NH), 7.85 (s, 1H, H-6), 6.10 (t, 1H, J = 6.9
Hz, H-10), 4.29 (s, 1H, H-30), 3.88 (m, 1H, H-40), 3.80 (m, 2H, H-50),
3.01 (m, 2H, CH2N), 2.36 (t, 2H, J = 6.9 Hz, R-CH2), 2.192.03 (m,
2H, H-20), 2.09 (t, 2H, J = 7.4 Hz, CH2CO), 1.61 (m, 2H, CH2), 1.47
(m, 2H, CH2), 1.36 (m, 2H, CH2), 1.24 (m, 2H, CH2), 0.84 (t, 3H, J =
7.3 Hz, CH3).
13C NMR (125 MHz, DMSO-d6) δ 172.02, 161.84,
149.58, 142.57, 99.49, 93.52, 86.35 (d, 1C, JCP = 6.7 Hz), 84.52, 72.81,
70.85, 64.15, 40.51, 38.16, 35.08, 31.38, 27.69, 24.93, 19.70, 18.68, 13.80.
31P NMR (121 MHz, DMSO-d6) δ 1.41. HRMS (ESI) calcd for
C20H29N3O9P 486.1647 (M  Hþ); found 486.1630.
1-β-D-Arabinofuranosyluracil-5-(N-butyl)heptynamide-50-
monophosphate (4b). This compound was prepared according to
the general procedure B described above. The following amounts of
starting material and reagents were employed: compound 14b (160 mg,
0.378mmol), POCl3 (53 μL, 0.567 mmol), and proton sponge (121mg,
0.567 mmol) in 1.5 mL of PO(OMe)3. The reaction mixture was stirred
at 0 C for 3 h and worked up as described above, including silica gel
column chromatography (2-propanol/NH4OH/H2O = 74:17.5:3.5f
70:20:5) and RP-HPLC (4 mM aq TEAB/CH3CN = 90:10, isocratic,
16 mL/min), yielding title compound 4b (56 mg, 27%) as a white solid;
mp >186 C (dec). 1HNMR (500MHz, D2O) δ 7.81 (s, 1H, H-6), 6.13
(d, 1H, J = 4.7 Hz, H-10), 4.30 (dd, 1H, J = 4.6, 3.6 Hz, H-20), 4.17 (dd,
1H, J = 4.7, 3.6 Hz, H-30), 4.063.95 (m, 3H, H-40 and H-50), 3.14 (t,
2H, J = 6.9 Hz, CH2N), 2.40 (t, 2H, J = 7.1 Hz, R-CH2), 2.25 (t, 2H, J =
7.3 Hz, CH2CO), 1.731.66 (m, 2H, CH2), 1.581.51 (m, 2H, CH2),
1.461.39 (m, 2H, CH2), 1.311.23 (m, 2H, CH2), 0.85 (t, 3H, J = 7.3
Hz, CH3).
13CNMR(125MHz, D2O)δ 176.29, 174.03, 157.28, 143.57,
98.72, 93.66, 85.35, 81.81 (d, 1C, JCP = 7.8 Hz), 75.79, 74.86, 73.46,
63.12 (d, 1C, JCP = 4.4 Hz), 38.64, 34.90, 30.03, 26.79, 24.53, 18.97,
18.06, 12.55. 31P NMR (121 MHz, DMSO-d6) δ 1.61. HRMS (ESI)
calcd for C20H30N3O10P 502.1596 (M  Hþ); found 502.1570.
N-(3-(5-(20-Deoxyuridine-50-monophosphate))prop-2-ynyl)-
octanamide (5a). This compound was prepared according to the
general procedure B described above. The following amounts of starting
material and reagents were employed: compound 18a (147.2 mg, 0.361
mmol), POCl3 (101 μL, 1.08 mmol), and proton sponge (235 mg, 1.09
mmol) in 2.5 mL of PO(OMe)3. The reaction mixture was stirred at 0 C
for 3 h and worked up as described above, including silica gel column
chromatography (2-propanol/NH4OH/H2O = 85:10:5f80:10:10f
75:15:10) and RP-HPLC (30 mM aq TEAB/CH3CN = 85:15f
80:20f75:25, 16 mL/min), yielding title compound 5a (16 mg, 8%) as
a white solid; mp >171 C (dec). 1H NMR (500 MHz, D2O) δ 8.12 (s,
1H, H-6), 6.23 (t, 1H, J = 6.7 Hz, H-10), 4.51 (m, 1H, H-30), 4.13 (br m,
3H,R-CH2 and H-40), 3.94 (t, 2H, J = 5 Hz, H-50), 2.402.28 (br m, 2H,
H-20), 2.24 (t, 2H, J = 7.3 Hz, CH2CO), 1.57 (m, 2H, CH2CH2CO),
1.291.11 (brm, 8H, 4CH2), 0.78 (t, 3H, J = 7.0Hz, CH3). 13CNMR
(125MHz, D2O)δ 176.97, 164.33, 150.20, 144.51, 98.73, 89.65, 85.61 (d,
1C, JCP = 8.5 Hz), 85.34, 72.99, 70.49, 63.52 (d, 1C, JCP = 4.4 Hz), 38.27,
35.18, 30.64, 29.09, 27.68, 27.58, 24.89, 21.49, 12.97. 31P NMR (121
MHz, D2O) δ 2.68. HRMS (ESI) calcd for C20H30N3O9P 486.1647
(M  Hþ); found 486.1655.
N-(3-(5-(20-Deoxyuridine-50-monophosphate))prop-2-ynyl)-
hexanamide (5b). This compound was prepared according to the
general procedure A described above. The reaction mixture was worked
up as described above, including silica gel column chromatography (2-
propanol/NH4OH/H2O = 70:20:5) and RP-HPLC (4 mM aq TEAB/
CH3CN = 88:12f75:25, 16 mL/min), followed by a second run
(30 mM aq TEAB/CH3CN = 87:13, isocratic, 7 mL/min), yielding
title compound 5b (15.7mg, 7%) as a white solid; mp >161 C (dec). 1H
NMR (500 MHz, D2O) δ 8.17 (s, 1H, H-6), 6.28 (t, 1H, J = 6.7 Hz,
H-10), 4.56 (m, 1H, H-30), 4.18 (br m, 1H, H-40), 4.17 (s, 2H, R-CH2),
4.05 (m, 2H, H-50), 2.472.34 (br m, 2H, H-20), 2.29 (t, 2H, J = 7.4 Hz,
CH2CO), 1.61 (m, 2H, CH2CH2CO), 1.351.20 (br m, 4H, 2CH2),
0.86 (t, 3H, J = 7.0 Hz, CH3).
13C NMR (125 MHz, D2O) δ 177.29,
164.62, 150.52, 144.86, 99.07, 89.89, 85.86 (d, 1C, JCP =8.4 Hz), 73.47,
70.79, 64.29 (d, 1C, JCP = 4.3 Hz), 38.93, 35.59, 30.42, 29.55, 24.93,
21.66, 13.20. 31P NMR (121 MHz, D2O) δ 1.23. HRMS (ESI) calcd for
C18H26N3O9P 458.1334 (M  Hþ); found 458.1338.
N-(3-(5-(20-Deoxyuridine-50-monophosphate))prop-2-ynyl)-
butanamide (5c). This compound was prepared according to the
general procedure A described above. The reaction mixture was worked
up as described above, including silica gel column chromatography (2-
propanol/NH4OH/H2O = 70:20:5) and RP-HPLC (10 mM aq TEAB/
CH3CN= 94:6f80:20, 16mL/min), followed by a second run (30mM
aq TEAB/CH3CN = 92:8, isocratic, 7 mL/min), yielding title com-
pound 5c (53 mg, 28%) as a white solid; mp >168 C (dec). 1H NMR
(500MHz, D2O) δ 8.12 (s, 1H, H-6), 6.27 (t, 1H, J = 6.8 Hz, H-10), 4.55
(m, 1H, H-30), 4.19 (s, 1H,R-CH2), 4.16 (m, 1H, H-40), 4.013.90 (m,
2H, H-50), 2.452.34 (br m, 2H, H-20), 2.27 (t, 2H, J = 7.4 Hz,
CH2CO), 1.62 (m, 2H, CH2CH2CO), 0.92 (t, 3H, J = 7.4Hz, CH3).
13C
NMR (125 MHz, D2O) δ 177.04, 160.24, 151.57, 144.77, 99.08, 89.73,
86.04 (d, 1C, JCP = 8.2 Hz), 85.65, 73.84, 70.97, 63.70 (d, 1C, JCP = 4.5
Hz), 38.50, 37.50, 29.55, 18.84, 12.70. 31P NMR (121 MHz, D2O) δ
4.01. HRMS (ESI) calcd for C16H22N3O9P 430.1021 (MHþ); found
430.1017.
2-Phenyl-N-(3-(5-(20-deoxyuridine-50-monophosphate))-
prop-2-ynyl)acetamide (5d). Compound 23 (110 mg, 0.25 mmol)
and 2-cyanoethyl phosphate (pyridinium salt, 0.1 M stock solution in
H2O/pyridine; 5 mL, 0.5 mmol) were evaporated and coevaporated
with dry pyridine (2 2 mL) and then dissolved in dry pyridine (3 mL)
under an Ar atmosphere. DCC (309mg, 1.5 mmol) was then added, and
the reaction mixture was stirred at rt for 2 1/2 days, after which time the
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solvent was evaporated. The residue was taken up 1 M NaOH (2 mL)
and stirred at 100 C for 5min. Themixture was allowed to cool down to
rt, and the pH was adjusted to≈89 (dropwise addition of AcOH) and
the volatiles were removed in vacuo. The residue was subjected to a
column of silica gel (2-PrOH/NH4OH/H2O = 90:5:5f80:10:10) and
to RP-HPLC (C-18, 10 mM aq TEAB/CH3CN = 90:10, isocratic,
16mL/min). Appropriate fractions were pooled and lyophilized, and the
obtained product was converted into its disodium salt by passage
through a column of Dowex 50-WX8 (Naþ-form) and elution with
H2O. After evaporation of the solvent and lyophilization, compound 5d
(21 mg, 16%) was obtained as a white solid; mp >174 C (dec). 1H
NMR (500MHz, D2O) δ 7.98 (s, 1H, H-6), 7.36 (m, 5H, ArH), 6.28 (t,
1H, J = 6.9 Hz, H-10), 4.51 (m, 1H, H-30), 4.16 (s, 2H,R-CH2), 4.11 (m,
1H, H-40), 3.92 (m, 2H, H-50), 3.64 (s, 2H, CH2Ph), 2.34 (m, 2H, H-20).
13C NMR (125 MHz, D2O) δ 174.21, 172.60, 156.60, 143.64, 134.47,
128.92 (2C), 128.61 (2C), 126.99, 98.74, 88.01, 85.33 (d, 1C, JCP = 8.2
Hz), 85.13, 75.78, 70.77, 63.44 (d, 1C, JCP = 4.5Hz), 41.91, 38.25, 29.63.
31P NMR (121 MHz, D2O) δ 3.99. HRMS (ESI) calcd for
C20H22N3O9P 478.1021 (M  Hþ); found 478.1020.
N-(3-(5-(20-Deoxyuridine-50-monophosphate))prop-2-ynyl)-
heptane-1-sulfonamide (6a). Compound 24 (121 mg, 0.25 mmol),
HOBt (38 mg, 0.25 mmol), and 2-cyanoethyl phosphate (pyridinium salt,
0.1 M stock solution in H2O/pyridine; 6.25 mL, 0.625 mmol) were
evaporated and coevaporated with dry pyridine (3 2mL), then dissolved
in dry pyridine (3mL) under an Ar-atmosphere. DCC (309mg, 1.5mmol)
was then added, and the reaction mixture was stirred at rt for 2 days, after
which time the solvent was evaporated. The residue was taken up 1 M
NaOH (2mL) and stirred at 100 C for 5min. Themixture was allowed to
cool down to rt and the pH was adjusted to ≈89 (dropwise addition of
AcOH) and the volatiles were removed in vacuo. The residue was subjected
to a column of silica gel (2-PrOH/NH4OH/H2O = 90:5:5f75:15:10)
and to RP-HPLC (C-18, 10 mM aq TEAB/CH3CN = 80:20, isocratic,
16 mL/min). Appropriate fractions were pooled and lyophilized, and
the obtained product was converted into its disodium salt by passage
through a column of Dowex 50-WX8 (Naþ-form) and elution with
H2O. After evaporation of the solvent and lyophilization, compound
6a (15 mg, 11%)was obtained as a white solid; mp >175 C (dec). 1H
NMR (500 MHz, D2O) δ 8.19 (s, 1H, H-6), 6.21 (t, 1H, J = 6.8 Hz,
H-10), 4.50 (m, 1H, H-30), 4.11 (m, 1H, H-40), 4.08 (s, 2H, R-CH2),
3.93 (m, 2H, H-50), 3.28 (m, 2H, CH2SO2), 2.392.27 (m, 2H,
H-20), 1.72 (m, 2H, CH2), 1.28 (m, 2H, CH2), 1.191.09 (m, 6H,
3CH2), 0.74 (t, 3H, J = 6.9 Hz, CH3). 13C NMR (125 MHz, D2O)
δ 164.14, 150.14, 144.77, 98.51, 89.36, 85.70 (d, 1C, JCP = 7.5 Hz),
85.36, 74.63, 70.41, 63.41, 51.66, 38.43, 32.16, 30.56, 27.62,
27.06, 22.52, 21.52, 12.86. 31P NMR (121 MHz, D2O) δ 2.72.
HRMS (ESI) calcd for C19H30N3O10PS 522.1317 (MHþ); found
522.1310.
1-Hexyl-(3-(5-(20-deoxyuridine-50-monophosphate))prop-
2-ynyl)urea (6b).Crude 25 (228mg, 0.51mmol), HOBt (77mg, 0.51
mmol), and 2-cyanoethyl phosphate (pyridinium salt, 0.1 M stock
solution in H2O/pyridine; 15 mL, 1.5 mmol) were evaporated and
coevaporated with dry pyridine (3  5 mL) and then dissolved in dry
pyridine (6 mL) under an Ar atmosphere. DCC (625 mg, 3.04 mmol)
was then added, and the reaction mixture was stirred at 4045 C for
2 days, after which time the solvent was evaporated. The residue was taken
up 1 MNaOH (7 mL) and stirred at 100 C for 5 min. The mixture was
allowed to cool down to rt and the pH was adjusted to≈89 (dropwise
addition of AcOH) and the volatiles were removed in vacuo. The residue
was subjected to a column of silica gel (2-PrOH/NH4OH/H2O =
90:5:5f75:15:10) and to RP-HPLC (C-18, 10 mM aq TEAB/CH3CN =
85:15, isocratic, 16 mL/min). Appropriate fractions were pooled and
lyophilized, and the obtained product was converted into its disodium
salt by passage through a column of Dowex 50-WX8 (Naþ-form) and
elution with H2O. After evaporation of the solvent and lyophilization,
compound 6b (26 mg, 9%) was obtained as a white solid; mp >169 C
(dec). 1H NMR (500 MHz, D2O) δ 8.19 (s, 1H, H-6), 6.29 (t, 1H, J =
6.8 Hz, H-10), 4.57 (m, 1H, H-30), 4.17 (m, 1H, H-40), 4.09 (d, 2H, J =
1.8 Hz, R-CH2), 3.97 (m, 2H, H-50), 3.13 (td, 2H, J = 6.8, 1.3 Hz,
CH2NH), 2.452.36 (m, 2H, H-20), 1.49 (m, 2H, CH2), 1.341.24 (m,
6H, 3  CH2), 0.85 (t, 3H, J = 7.1 Hz, CH3). 13C NMR (125 MHz,
D2O) δ 164.60, 160.07, 150.41, 144.52, 98.90, 91.11, 85.76 (d, 1C, JCP =
8.8 Hz), 85.28, 72.98, 70.50, 63.33 (d, 1C, JCP = 3.8 Hz), 39.56, 38.28,
30.45, 30.01, 28.75, 25.26, 21.60, 12.92. 31P NMR (121 MHz, D2O) δ
3.43. HRMS (ESI) calcd for C19H29N4O9P 487.1599 (MHþ); found
487.1585.
Cloning, Expression, and Purification of Mycobacterial
ThyX. This was done according to protocols described.21
ThyX-Inhibition Assay. The tritium-release assay was adapted
fromHunter et al.56 Briefly, the reaction was performed in a final volume
of 25 μL, in a 96-well flat bottom plate, including 1.5 μg of M.
tuberculosis ThyX, 20 μM homemade mTHF, 10 μM FAD and
500 μM NADPH, and compounds if required. Reaction was initiated by
addition of 10 μL of 2 μM [5-3H] dUMP (13 Ci/mmol). After a 10 min
reaction period, at room temperature, the reaction was terminated by the
addition of 20 μL of a stop solution (a 3:1 ratio of 2 N TCA:4.3 mM
dUMP). To remove unreacted substrates, 150 μL of 10% (w/v)
activated charcoal in water was added to the reaction mixture. The plate
was incubated on ice for 15min and then centrifuged at 3800g at 4 C for
10 min. A 100 μL aliquot of the supernatant was assayed by liquid
scintillation counting to determine the amount of tritium-containing
water produced by the reaction. Percentages of activity compared to
control points were calculated and IC50 values determined.
Cloning, Expression, and Purification of Mycobacterial
ThyA. Cloning. PCR reactions were performed using a BioRad MJ
Mini Personal Thermal Cycler. Primers were purchased from Euro-
gentech: 50-CTTGACCATATGGGCCATCATCATCATCATCACG-
GCACGCC ATACGAGGACCTGCTG, 50-CTAGTCGGATCCT-
CATACCGCGACTGGAGC cDNA containing ThyA gene was used
as a template. PCR reactions were carried out using Ex Taq polymerase
and standard reaction conditions (Ta 55 C). Reactions were purified
using QIAquick PCR purification kit (Qiagen). NdeI and BamHI
restrictions enzymes (BioLabs) were used to create sticky ends on the
ThyA PCR-fragment, and manufacturer’s standard reaction conditions
were used. Pet3a vector was also cut with NdeI and BamHI restriction
enzymes and treated with alkaline phosphatase. Afterward, pet3a vector
was purified from 0.8% agarose gel using QIAEXII Gel extraction kit
(Qiagen). Ligation reaction (T4 DNA ligase, BioLabs) was performed
according to manufacturer’s instructions. TG1 E. coli RbCl chemical
competent cells were transformed with the ligation mixture, grown
during 1 h at 37 C and 250 rpm in 900 μL LB-medium and then plated
on the LB agar plates and grown overnight at 37 C. Several colonies
were picked up for colony PCR and also overnight cultures in LB
medium were set up. Pet3a plasmid of a positive colony was purified
from an overnight culture using QIAprep Spin Miniprep kit (Qiagen),
and the concentration was measured using NANODROP 1000.
Expression. BL21 (DE3) pLysS E. coli RbCl chemical competent cells
were transformed with pet3a vector containing the ThyA insert, grown
during 1 h at 37 C and 250 rpm in 900 μL LB-medium, then plated on
the LB-agar plates and grown overnight at 37 C. Afterward, a colony
was picked up into an overnight culture. Bacteria from the overnight
culture were grown in 1 L LBmedium at 37 C and 250 rpm until OD600 =
0.60.8 and then induced with 200 μL 1 M IPTG solution and grown
overnight at 22 C and 250 rpm. Bacteria were spun down for 10 min at
10000 rpm and 4 C. The obtained bacterial pellet was stored at20 C.
Purification. The bacterial pellet was resuspended in 10 mL of lysis
buffer containing 5 mg of lysozyme, 1 mM DTT, and protease inhibitor
cocktail. After five times, French Press lysate was spun down for 20 min.
ThyA protein was purified from supernatants using His6-based affinity
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chromatography (NTA magnetic beads, Qiagen) according to the
manufacturer’s instructions.
ThyA-Inhibition Assay. ThyA activity was adapted from Kan
et al.58 In brief, the reaction mixture (100 μL) contained 1 μg of ThyA
enzyme, 50mMTris-HCl (pH 7.5), 500 μMhomemademTHF, 10mM
MgCl2, and compound if required. Reactions, performed at room
temperature in a 96-well flat bottom plate, were initiated by addition
of 20 μL of 2 mM dUMP. The increase in absorbance at 340 nm was
measured directly after dUMP addition and after 30 min, using a
spectrophotometer (envision, Perkin elmer). Percentages of activity
compared to control points (no enzyme, no inhibitor) were calculated
and IC50 values determined.
’ASSOCIATED CONTENT
bS Supporting Information. Experimental procedures for
the synthesis of compounds 10ab, 11ab, 15ad, 2122,
and purity of synthesized derivatives 12, 3ab, 4ab, 5ad,




*Phone: þ32 16 337387. Fax: þ32 16 337340. E-mail: Piet.
Herdewijn@rega.kuleuven.be.
’ACKNOWLEDGMENT
We are grateful to Prof. Roger Busson for his kind assistance
and his expertise regarding the interpretation of complex product
mixtures by NMR spectroscopy and Luc Baudemprez for run-
ning 500 and 600 MHz NMR spectra. This work was partly
funded by a collaborative project grant (NATT-project) from the
European Commission. Martin K€ogler is deeply indebted to the
IWT (Agentschap voor Innovatie door Wetenschap en Tech-
nologie) for providing a Ph.D. scholarship.
’ABBREVIATIONS USED
AcOH, acetic acid; Ac2O, acetic anhydride; CAN, cerium(IV)-
ammonium nitrate;CH2THF, methylenetetrahydrofolic acid; DCC,
dicyclohexylcarbodiimide; DCM, dichloromethane; DHF, dihy-
drofolate; DHFR, dhydrofolate reductase; DIAD, diisopropyl
azodicarboxylate; DIC, diisopropycarbodiimide; DIPEA, diiso-
propylethylamine; DMAP, 4-dimethylaminopyridine; DMF, di-
methylformamide; DMSO, dimethylsulfoxide; DMTrCl, 4,40-
dimethoxytrityl chloride; dTMP, 20-deoxythymidine-50-mono-
phosphate; dUMP, 20-deoxyuridine-50-monophosphate; EDTA,
ethylenediamine tetraacetic acid; EtOAc, ethyl acetate; EtOH,
ethanol; FAD, flavin adenine dinucleotide; FDTS, flavin-depen-
dent thymidylate synthase; HIV, human immunodeficiency
virus; HOBt, hydroxybenzotriazole; IC50, half maximal (50%)
inhibitory concentration;MDR-TB, multi drug-resistant TB;MeOH,
methanol;MIC90, minimum inhibitory concentration 90%;NADPH,
nicotinamide adenine nucleotide phosphate hydride;NEt3, triethyla-
mine; RP-HPLC, reversed-phase high performance liquid chro-
matography; rt, room temperature; SAR, structureactivity
relationship; SHMT, serine hydroxymethyl transferase; TB, tuber-
culosis; TCA, trichloroacetic acid;TEAB, triethylammonium bicar-
bonate; THF, tetrahydrofuran;ThyA, thymidylate synthase;ThyX,
flavin-dependent thymidylate synthase;TMSI, trimethylsilyl iodide;
TS, thymidylate synthase;WHO, World Health Organization;
XDR, extensively drug resistant
’REFERENCES
(1) World Health Organization Global TB Control Report, 2010.
(2) Ducati, R. G.; Ruffino-Netto, A.; Basso, L. A.; Santos, D. S. The
resumption of consumption—a review on tuberculosis. Mem. Inst.
Oswaldo Cruz 2006, 101, 697–714.
(3) Glickman, M. S.; Jacobs, W. R. Microbial pathogenesis of
Mycobacterium tuberculosis: dawn of a discipline. Cell 2001, 104,
477–485.
(4) Hershfield, E. Tuberculosis: 9. Treatment. Can. Med. Assov. J.
1999, 161, 405–411.
(5) Janin, Y. L. Antituberculosis drugs: ten years of research. Bioorg.
Med. Chem. 2007, 15, 2479–2513.
(6) Saltini, C. Chemotherapy and diagnosis of tuberculosis. Respir.
Med. 2006, 100, 2085–2097.
(7) Yee, D.; Valiquette, C.; Pelletier, M.; Parisien, I.; Rocher, I.;
Menzies, D. Incidence of serious side effects from first-line antitubercu-
losis drugs among patients treated for active tuberculosis. Am. J. Respir.
Crit. Care Med. 2003, 167, 1472–1477.
(8) FitzGerald, J. M.; Houston, S. Tuberculosis: 8. The disease in
association with HIV infection. Can. Med. Assoc. J. 1999, 161, 47–51.
(9) Zignol, M.; Hosseini, M. S.; Wright, A.; Lambregts-van
Weezenbeek, C.; Nunn, P.; Watt, C. J.; Williams, B. G.; Dye, C. Global
incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 2006,
194, 479–485.
(10) Haydel, S. E. Extensively Drug-Resistant Tuberculosis: A Sign
of the Times and an Impetus for Antimicrobial Discovery. Pharmaceu-
ticals 2010, 3, 2268–2290.
(11) Gmeiner, W. H. Novel chemical strategies for thymidylate
synthase inhibition. Curr. Med. Chem. 2005, 12, 191–202.
(12) Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K.
The challenge of new drug discovery for tuberculosis. Nature 2011,
469, 483–490.
(13) Carreras, C. W.; Santi, D. V. The Catalytic Mechanism and
Structure of Thymidylate Synthase. Annu. Rev. Biochem. 1995, 64,
721–762.
(14) Myllykallio, H.; Lipowski, G.; Leduc, D.; Filee, J.; Forterre, P.;
Liebl, U. An alternative flavin-dependent mechanism for thymidylate
synthesis. Science 2002, 297, 105–107.
(15) Mathews, I. I.; Deacon, A. M.; Canaves, J. M.; McMullan, D.;
Lesley, S. A.; Agarwalla, S.; Kuhn, P. Functional analysis of substrate and
cofactor complex structures of a thymidylate synthase-complementing
protein. Structure 2003, 11, 677–690.
(16) Rengarajan, J.; Bloom, B. R.; Rubin, E. J. Genome-wide
requirements for Mycobacterium tuberculosis adaptation and survival in
macrophages. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 8327–8332.
(17) Sassetti, C. M.; Boyd, D. H.; Rubin, E. J. Genes required for
mycobacterial growth defined by high density mutagenesis. Mol. Micro-
biol. 2003, 48, 77–84.
(18) Leduc, D.; Escartin, F.; Nijhout, H. F.; Reed, M. C.; Liebl, U.;
Skouloubris, S.; Myllykallio, H. Flavin-dependent thymidylate synthase
ThyX activity: implications for the folate cycle in bacteria. J. Bacteriol.
2007, 189, 8537–8535.
(19) Agrawal, N.; Lesley, S. A.; Kuhn, P.; Kohen, A. Mechanistic
studies of a flavin-dependent thymidylate synthase. Biochemistry 2004,
43, 10295–10301.
(20) Graziani, S.; Bernauer, J.; Skouloubris, S.; Graille, M.; Zhou,
C. Z.;Marchand, C.; Decottignies, P.; van Tilbeurgh, H.;Myllykallio, H.;
Liebl, U. Catalytic mechanism and structure of viral flavin-dependent
thymidylate synthase ThyX. J. Biol. Chem. 2006, 281, 24048–24057.
(21) Sampathkumar, P.; Turley, S.; Ulmer, J. E.; Rhie, H. G.; Sibley,
C. H.; Hol, W. G. Structure of the Mycobacterium tuberculosis flavin
dependent thymidylate synthase (MtbThyX) at 2.0A resolution. J. Mol.
Biol. 2005, 352, 1091–1104.
4862 dx.doi.org/10.1021/jm2004688 |J. Med. Chem. 2011, 54, 4847–4862
Journal of Medicinal Chemistry ARTICLE
(22) Koehn, E. M.; Fleischmann, T.; Conrad, J. A.; Palfey, B. A.;
Lesley, S. A.; Mathews, I. I.; Kohen, A. An unusual mechanism of
thymidylate biosynthesis in organisms containing the ThyX gene.
Nature 2009, 458, 919–923.
(23) Graziani, S.; Xia, Y.; Gurnon, J. R.; Van Etten, J. L.; Leduc, D.;
Skouloubris, S.; Myllykallio, H.; Liebl, U. Functional analysis of FAD-
dependent thymidylate synthase ThyX from Paramecium bursaria
Chlorella virus-1. J. Biol. Chem. 2004, 279, 54340–54347.
(24) Danenberg, P. V.; Langenbach, R. J.; Heidelberger, C. Struc-
tures of Reversible and Irreversible Complexes of Thymidylate Synthe-
tase and Fluorinated Pyrimidine Nucleotides. Biochemistry 1974,
13, 926–933.
(25) Heidelberger, C.; Chaudhuri, N. K.; Danneberg, P.; Mooren,
D.; Griesbach, L.; Duschinsky, R.; Schnitzer, R. J.; Pleven, E.; Scheiner, J.
Fluorinated Pyrimidines, a New Class of Tumour-Inhibitory Com-
pounds. Nature 1957, 179, 663–666.
(26) Heidelberger, C.; Ghobar, A.; Baker, R. K.; Mukherjee, K. L.
Studies on Fluorinated Pyrimidines. 10. In vivo Studies on Tumor
Resistance. Cancer Res. 1960, 20, 897–902.
(27) Heidelberger, C.; Kaldor, G.; Mukherjee, K. L.; Danneberg,
P. B. Studies on Fluorinated Pyrimidines. 11. In vitro Studies on Tumor
Resistance. Cancer Res. 1960, 20, 903–909.
(28) Santi, D. V.; McHenry, C. S.; Sommer, H. Mechanism of
Interaction of Thymidylate Synthetase with 5-Fluorodeoxyuridylate.
Biochemistry 1974, 13, 471–481.
(29) Asakura, J.; Robins, M. J. Cerium(IV)-mediated Halogenation
at C-5 of Uracil Derivatives. J. Org. Chem. 1990, 55, 4928–4933.
(30) Goodchild, J.; Porter, R. A.; Raper, R. H.; Sim, I. S.; Upton,
R. M.; Viney, J.; Wadsworth, H. J. Structural Requirements of Olefinic
5-Substituted Deoxyuridines for Antiherpes Activity. J. Med. Chem.
1983, 26, 1252–1257.
(31) Ogino, M.; Yoshimura, Y.; Nakazawa, A.; Saito, I.; Fujimoto, K.
Template-directed DNA photoligation via alpha-5-cyanovinyldeoxyur-
idine. Org. Lett. 2005, 7, 2853–2856.
(32) Whale, R. F.; Coe, P. L.; Walker, R. T. The Synthesis of Some
5-Vinyluracil-Nucleoside Analogs. Nucleosids, Nucleotides 1991, 10,
1615–1624.
(33) Sowa, T.; Ouchi, S. Facile Synthesis of 50-Nucleotides by
Selective Phosphorylation of a Primary Hydroxyl Group of Nucleo-
sides with Phosphoryl Chloride. Bull. Chem. Soc. Jpn. 1975, 48, 2084–
2090.
(34) Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling
Reactions of Organoboron Compounds.Chem. Rev. 1995, 95, 2457–2483.
(35) Robins, M. J.; Barr, P. J. Nucleic-Acid Related-Compounds. 39.
Efficient Conversion of 5-Iodo to 5-Alkynyl and Derived 5-Substituted
Uracil Bases and Nucleosides. J. Org. Chem. 1983, 48, 1854–1862.
(36) Robins,M. J.; Vinayak, R. S.;Wood, S. G. Nucleic-Acid Related-
Compounds. 59. Solvent, Not PalladiumOxidation-State, is the Primary
Determinant for Successful Coupling of Terminal Alkynes with Iodo-
Nucleosides. Tetrahedron Lett. 1990, 31, 3731–3734.
(37) Summerer, D.; Marx, A. DNA polymerase selectivity: sugar
interactions monitored with high-fidelity nucleotides. Angew. Chem., Int.
Ed. 2001, 40, 3693–3695.
(38) Yoshikawa, M; Kato, T.; Takenish., T. Studies of Phosphoryla-
tion. 3. Selective Phosphorylation of Unprotected Nucleosides. Bull.
Chem. Soc. Jpn. 1969, 42, 3505–3508.
(39) Schinazi, R. F.; Chen, M. S.; Prusoff, W. H. Anti-Viral and Anti-
Neoplastic Activities of Pyrimidine Arabinosyl Nucleosides and Their
50-Amino Derivatives. J. Med. Chem. 1979, 22, 1273–1277.
(40) Hampton, A.; Nichol, A. W. Nucleotides. V. Purine Ribonu-
cleoside 20,30-Cyclic Carbonates. Preparation and Use for Synthesis of
50-Monosubstituted Nucleosides. Biochemistry 1966, 5, 2076–2082.
(41) Robins, M. J.; Manfredini, S.; Wood, S. G.; Wanklin, R. J.;
Rennie, B. A.; Sacks, S. L. Nucleic-Acid-Related Compounds. 65. New
Syntheses of 1-(β-D-Arabinofuranosyl)-5(E)-(2-Iodovinyl)Uracil (IVaraU)
from Vinylsilane Precursors—Radioiodine Uptake as a Marker for
Thymidine Kinase Positive Herpes Viral Infections. J. Med. Chem.
1991, 34, 2275–2280.
(42) Sharma, R. A.; Kavai, I.; Hughes, R. G.; Bobek, M. Acetylenic
Nucleosides. 3. Synthesis and Biological Activities of Some 5-Ethynyl-
pyrimidine Nucleosides. J. Med. Chem. 1984, 27, 410–412.
(43) Zhao, Z.; Peng, G.; Michels, J.; Fox, K. R.; Brown, T. Synthesis
of anthraquinone oligonucleotides for triplex stabilization. Nucleosides
Nucleotides Nucleic Acids 2007, 26, 921–925.
(44) VanCalenbergh, S.; von Frijtag, J. K.; Kunzel, D.; Blaton, N.M.;
Peeters, O. M.; Rozenski, J.; Van Aerschot, A.; De Bruyn, A.; De
Keukeleire, D.; Ijzerman, A. P.; Herdewijn, P. N-6-Cyclopentyl-30-
substituted-xylofuranosyladenosines: a new class of non-xanthine ade-
nosine A(1) receptor antagonists. J. Med. Chem. 1997, 40, 3765–3772.
(45) Nomura, R.; Tabei, J.; Masuda, T. Effect of side chain structure
on the conformation of poly(N-propargylalkylamide). Macromolecules
2002, 35, 2955–2961.
(46) Bello, A. M.; Konforte, D.; Poduch, E.; Furlonger, C.; Wei, L.;
Liu, Y.; Lewis, M.; Pai, E. F.; Paige, C. J.; Kotra, L. P. Structure-Activity
Relationships of Orotidine-50-Monophosphate Decarboxylase Inhibi-
tors as Anticancer Agents. J. Med. Chem. 2009, 52, 1648–1658.
(47) Mitsunobu, O.; Kato, K.; Kimura, J. Selective Phosphorylation
of 50-Hydroxy Groups of Thymidine and Uridine. J. Am. Chem. Soc.
1969, 91, 6510–6511.
(48) Brown, R. T.; Murrell, V. L.; McMordie, A.; Sriram, M.; Pinney,
K. G.; Sharma, S.; Chaplin, D. J. Carbon-14 radiosynthesis of combre-
tastatin A-1 (CA1) and its corresponding phosphate prodrug (CA1P). J.
Labelled Compd. Radiopharm. 2009, 52, 567–570.
(49) Tener, G. M. 2-Cyanoethyl Phosphate and Its Use in Synthesis
of Phosphate Esters. J. Am. Chem. Soc. 1961, 83, 159–168.
(50) Matsuda, A.; Shinozaki, M.; Suzuki, M.; Watanabe, K.; Miya-
saka, T. A Convenient Method for the Selective Acylation of Guanine
Nucleosides. Synthesis 1986, 385–386.
(51) Rimoli, M. G.; Avallone, L.; de Caprariis, P.; Galeone, A.; Forni,
F.; Vandelli, M. A. Synthesis and characterisation of poly(D,L-lactic acid)
idoxuridine conjugate. J. Controlled Release 1999, 58, 61–68.
(52) Wang, J. S.; Wang, Y. S. Chemical synthesis of oligodeoxyr-
ibonucleotides containing N3-and O-4-carboxymethylthymidine and
their formation in DNA. Nucleic Acids Res. 2009, 37, 336–345.
(53) Noller, C. R.; Hearst, P. J. Preparation of methanesulfonyl
chloride. J. Am. Chem. Soc. 1948, 70, 3955.
(54) Hirsch, A. K. H.; Alphey, M. S.; Lauw, S.; Seet, M.; Barandun,
L.; Eisenreich,W.; Rohdich, F.; Hunter,W.N.; Bacherc, A.; Diederich, F.
Inhibitors of the kinase IspE: structureactivity relationships and co-
crystal structure analysis. Org. Biomol. Chem. 2008, 6, 2719–2730.
(55) Papesch, V.; Schroeder, E. F. Synthesis of 1-mono and 1,3-di-
substituted 6-aminouracils. Diuretic activity. J. Org. Chem. 1951, 16,
1879–1890.
(56) Hunter, J. H.; Gujjar, R.; Pang, C. K.; Rathod, P. K. Kinetics and
ligand-binding preferences of Mycobacterium tuberculosis thymidylate
synthases, ThyA and ThyX. PLoS One 2008, 3, e2237.
(57) Lomax, M. I. S.; Greenberg, R. A New Assay of Thymidylate
Synthetase Activity Based on Release of Tritium from Deoxyuridylate-
5-3H. J. Biol. Chem. 1967, 242, 109–113.
(58) Kan, S. C.; Liu, J. S.; Hu, H. Y.; Chang, C.M.; Lin,W. D.; Wang,
W. C.; Hsu, W. H. Biochemical characterization of two thymidylate
synthases in Corynebacterium glutamicum NCHU 87078. Biochim.
Biophys. Acta 2010, 1804, 1751–1759.
(59) Johar, M.; Manning, T.; Tse, C.; Desroches, N.; Agrawal, B.;
Kunimoto, D. Y.; Kumar, R. Growth inhibition of Mycobacterium bovis,
Mycobacterium tuberculosis, and Mycobacterium avium in vitro: Effect of
1-β-D-20-Arabinofuranosyl and 1-(20-Deoxy-20-fluoro-β-D-20-ribofuran-
osyl) pyrimidine nucleoside analogs. J. Med. Chem. 2007, 50, 3696–
3705.
